{"Title": ["Why Dynavax, Novavax, and Vir Biotechnology Stocks Jumped Today", "Is Alnylam a Good Biotech Stock to Buy Now?", "Alnylam To Present At The Goldman Sachs Global Healthcare Conference; Webcast At 8:00 AM ET", "Notable Tuesday Option Activity: FATE, NWL, ALNY", "Alnylam To Present At Jefferies Virtual Healthcare Conference; Webcast At 10:30 AM ET", "Vir Biotechnology Is Bucking The Biotech COVID-19 Trends, And Stands To Win", "Got $3,000? Here Are 3 Great Biotech Stocks to Buy Right Now", "Analysts Expect FXH To Hit $98", "Why Dynavax, Novavax, and Vir Biotechnology Stocks Jumped Today", "Is Arrowhead Pharmaceuticals a Buy?", "Better Coronavirus Stock: Gilead Sciences or Vir Biotechnology?", "Is Alnylam Pharmaceuticals a Buy?", "Alnylam Pharmaceuticals Inc (ALNY) Q1 2020 Earnings Call Transcript", "Alnylam Pharmaceuticals Lowers 2020 Sales Expectations Due to COVID-19", "Alnylam Pharmaceuticals Inc. Q1 adjusted earnings Beat Estimates", "Alnylam Q1 20 Earnings Conference Call At 8:30 AM ET", "ARGX Soars On ADAPT Trial Data, MRK's Deals & Collaborations To Fight COVID-19, ALNY ON Watch", "BUZZ-U.S. STOCKS ON THE MOVE-Airlines, banks, insurers, PG&E", "Vir Biotechnology and Alnylam Pick a Coronavirus Vaccine Candidate to Pursue", "Vir, Alnylam identify COVID-19 therapy candidate, plan human trials by year end", "Vir Biotechnology, Alnylam Identify VIR-2703 Candidate For Treatment Of COVID-19", "Vir, Alnylam pick coronavirus therapy candidate, plan human trials by year end", "Alnylam Pharmaceuticals Reaches Analyst Target Price", "Is Vir Biotechnology Stock a Buy?", "BUZZ-U.S. STOCKS ON THE MOVE-Airlines, banks, insurers, oil stocks", "Stock To Watch: Alnylam Pharma (ALNY)", "Financial Sector Update for 04/13/2020: LAMR,BX,ALNY,KKR,MFA", "Alnylam Scores a $2 Billion Investment From Blackstone", "Financial Sector Update for 04/13/2020: BX,ALNY,KKR,MFA", "BUZZ-U.S. STOCKS ON THE MOVE-Amazon.com, Netflix, Royal Caribbean Cruises, Sabre Corp, Pluristem Therapeutics", "Blackstone To Invest Up To $2 Bln In Alnylam", "Blackstone invests $2 bln in Alnylam, boosting gene-silencing drug development", "2 Top Small-Cap Stocks to Buy Right Now", "Better Buy: Alnylam Pharmaceuticals vs. Vir Biotechnology", "Analysts See 17% Upside For VUG", "Here Are All the Companies Working on COVID-19 Vaccines, Treatments, and Testing", "IMMU Soars, MLND Leaves Investors Starved, VIR, GSK To Develop COVID-19 Drugs", "Alnylam, Dicerna Form RNAi Therapeutics Collaboration For Alpha-1 Liver Disease", "FXH, DXCM, ALNY, SGEN: Large Inflows Detected at ETF", "Noteworthy Monday Option Activity: WLK, ALNY, LULU", "Blackstone invests $2 bln in Alnylam Pharma", "Why Alnylam Pharmaceuticals, Intuitive Surgical, and ResMed Stocks Sank Today", "Relative Strength Alert For Alnylam Pharmaceuticals", "Alnylam Pharma To Present At Barclays Global Conference; Webcast At 2:35 PM ET", "Analysts See 24% Gains Ahead For FXH", "WHO Says Coronavirus Death Rate Is Higher Than Previously Thought", "Vir Biotechnology and Alnylam Join the Fight Against COVID-19", "Alnylam To Cowen & Company Healthcare Conference; Webcast At 10:40 AM ET", "Better Coronavirus Stock: Inovio Pharmaceuticals vs. Vir Biotechnology", "Why Alnylam Pharmaceuticals, Intuitive Surgical, and ResMed Stocks Sank Today", "Relative Strength Alert For Alnylam Pharmaceuticals", "Alnylam Beats Revenue Estimates, but Misses on Earnings", "Alnylam Pharma Posts Wider Loss In Q4 - Quick Facts", "Alnylam Pharmaceuticals Inc. Q4 adjusted earnings Beat Estimates", "Alnylam Pharmaceuticals Q4 19 Earnings Conference Call At 8:30 AM ET", "Alnylam Pharma Says Givlaari Approved In EU For Acute Hepatic Porphyria", "Alnylam Pharma Reports Positive CHMP Opinion For Givosiran - Quick Facts", "Noteworthy Wednesday Option Activity: LLY, ALNY, MRVL", "First Week of ALNY September 18th Options Trading", "Noteworthy Friday Option Activity: ALNY, EHTH, PBYI", "Alnylam Pharma To Present At J.P. Morgan Conference; Webcast At 1:30 PM ET", "Why Alnylam Pharmaceuticals Rose 57.9% in 2019", "SPDR S&P Biotech ETF Experiences Big Outflow", "Peek Under The Hood: IWD Has 10% Upside", "These 2 Stocks Will Fall After the New Year", "Analysts Expect BBH To Hit $157", "XBI, ICPT, SGEN, ALNY: Large Inflows Detected at ETF", "3 Rare Disease Drug Launches to Watch in 2020", "These Were the 10 Best Healthcare Stocks of 2019", "USSG, IDNA: Big ETF Inflows", "Here's Why Dicerna Pharmaceuticals Is Falling Today", "These 3 Healthcare Stocks Are Set to Soar in 2020, Says Cowen", "Notable Thursday Option Activity: ETSY, BPMC, ALNY", "Alnylam Pharma To Present At Piper Jaffray Conference; Webcast At 9:00 AM ET", "Why Has Alnylam's Stock Gained 25% In The Last Two Weeks", "Why Has Alnylam's Stock Gained 25% In The Last Two Weeks", "Why Has Alnylam's Stock Gained 25% In The Last Two Weeks", "Here's Why Arrowhead Pharmaceuticals Is Tumbling Today", "Here's Why Alnylam Pharmaceuticals Rose 35.1% in November", "Reasons Behind The 40% Jump In Castle BioSciences\u2019 Stock Since Early November", "5 New Drug Approvals the FDA Gave Top Priority", "Commit To Purchase Alnylam Pharmaceuticals At $90, Earn 9.3% Using Options", "Better Buy: Editas Medicine or Sangamo Therapeutics?", "A 45% Premium: Here's Why The Medicines Company Is Worth More to Novartis Than It Was to You", "Why The Medicines Company Stock Is Soaring Today", "Is Alnylam Stock a Good Buy Now?", "Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class", "Does a Surprise Approval Make Alnylam Pharmaceuticals a Buy?", "3 Top Healthcare Stocks to Buy in November", "Here's Why The Medicines Company Moved Higher Today", "LPCN Awaits FDA Word, NKTR On Track, All's Well With Five Prime's FPT155", "Alnylam Pharmaceuticals Inc (ALNY) Q3 2019 Earnings Call Transcript", "These Biotechs Were Focused on One Line on Pfizer\u2019s Earnings Report", "Alnylam Pharma Q3 Loss Narrows On Strong Revenue Growth", "Alnylam Pharmaceuticals Q3 19 Earnings Conference Call At 8:30 AM ET", "Alnylam Expects To Exceed 2020 Goals With Four Marketed Products", "Why Did the Market Whack This IPO?", "The Medicines Company Surges on Positive Drug Trial Results", "The Medicines Company Is Up 161% Year to Date, but Here's a Better Way to Play the Drugmaker's Success", "ALNY Makes Notable Cross Below Critical Moving Average", "Notable ETF Outflow Detected - FBT, AMGN, NBIX, ALNY", "3 Biotech Stocks That Could Soar This Week", "Health Care Sector Update for 09/03/2019: ALNY, EMMA, AZN, CDTX", "Noteworthy Tuesday Option Activity: ALNY, SKX, SERV", "Here\u2019s Why The Medicines Company Shares Jumped 13.8% Today", "Analysts Predict 13% Upside For The Holdings of RXL", "Alnylam Pharmaceuticals Inc (ALNY) Q2 2019 Earnings Call Transcript", "Alnylam Pharmaceuticals Inc. Q2 adjusted earnings Beat Estimates", "Alnylam Pharmaceuticals (ALNY) Shares Cross Above 200 DMA", "Noteworthy Tuesday Option Activity: CXW, ALNY, ITGR", "8 More Big Pharma Events in 2019 You Don't Want to Miss", "XBI, GHDX, NVTA, ALNY: ETF Inflow Alert", "OSIZ's Underlying Holdings Could Mean 11% Gain Potential", "Interesting ALNY Put And Call Options For July 19th", "Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock", "Alnylam Pharmaceuticals is Now Oversold (ALNY)", "Alnylam Pharmaceuticals Continues Onpattro Launch With More to Come", "Can Alnylam Pharmaceuticals Stock Start Climbing Again?", "Alnylam Pharmaceuticals Inc (ALNY) Q1 2019 Earnings Call Transcript", "Analysts Forecast 10% Gains Ahead For VONV", "This Is Why You Shouldn\u2019t Count Regeneron Stock Out", "Is Alnylam Pharmaceuticals a Buy Now?", "Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran", "How The Parts Add Up: PBE Targets $69", "Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran", "4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics", "Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics", "Alnylam Pharmaceuticals Inc. Q1 adjusted earnings Beat Estimates", "This Is Why You Shouldn\u2019t Count Regeneron Stock Out", "Is Alnylam Pharmaceuticals a Buy Now?", "2 Biotechs With Big Dates in April", "Alnylam's (ALNY) Impressive Pipeline Drives Share Price", "Add Up The Pieces: IYH Could Be Worth $217", "Alnylam Files Application for Hypertension Candidate in UK", "First Week of ALNY May 17th Options Trading", "Alnylam Stock Down Despite Positive Phase III Givosiran Data", "U.S. STOCKS ON THE MOVE-Abercrombie & Fitch, Nio, Zayo, Titan Medical", "Alnylam's gene-silencing drug meets main goal in late-stage study", "Side effects of Alnylam's gene-silencing drug raise concerns, shares slip", "Can This Biotech Puppy Run With the Big Dogs?", "Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus", "Interesting ALNY Put And Call Options For April 18th", "Why Is Alnylam (ALNY) Up 3.1% Since Last Earnings Report?", "Alnylam Pharmaceuticals Is Launched and Ready for More", "Alnylam's (ALNY) Q4 Earnings and Revenues Beat Estimates", "Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2018 Earnings Conference Call Transcript", "Earnings Reaction History: Alnylam Pharmaceuticals Inc., 44.4% Follow-Through Indicator, 6.6% Sensitive", "First Week of ALNY September 20th Options Trading", "The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio", "5 Best Biotech Bets Likely to Outperform Estimates in Q4", "Is Moderna a Buy?", "Alnylam & Medison Partner to Market RNAi Products in Israel", "Alnylam Pharma, Medison Partner To Commercialize RNAi Therapeutics In Israel", "Health Care Sector Update for 01/15/2019: BPTH, ALNY, TRXC, JNJ, PFE, ABT, MRK, AMGN", "Health Care Sector Update for 01/15/2019: IRWD,KTOV,EW,BSX,ALNY", "Health Care Sector Update for 01/15/2019: MYOS,EW,BSX,ALNY", "We Did The Math IWB Can Go To $171", "Thursday's ETF Movers: FBT, GDXJ", "Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs", "Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4", "3 Things Alnylam's Management Wants You to Know", "Alnylam Pharma To Present At J.P. Morgan Conference; Webcast At 1:30 PM ET", "Health Care Sector Update for 12/28/2018: ALNY,IMMU,APHA,APHA.TO,VTVT", "RNAi Goes Big-Time in 2018", "Why Is Alnylam (ALNY) Up 9.2% Since Last Earnings Report?", "Alnylam, Vir Begin Phase I/II Study on Hepatitis B Candidate", "Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus", "Health Care Sector Update for 11/26/2018: ALNY,BHVN,EDGE", "Alnylam Pharmaceuticals Launches Onpattro", "Alnylam Pharmaceuticals is Now Oversold (ALNY)", "Ionis Pharmaceuticals Collects Royalties -- and Spends It All", "Medicines Company (MDCO) Q3 Loss Widens, Inclisiran in Focus", "Alnylam's (ALNY) Q3 Loss Narrower Than Expected, Sales Miss", "How The Parts Add Up: SIZE Targets $95", "Health Care Sector Update for 11/26/2018: RSLS,ALNY,EDGE,BHVN", "Earnings Reaction History: Alnylam Pharmaceuticals Inc., 37.5% Follow-Through Indicator, 6.2% Sensitive", "Alnylam Pharmaceuticals Inc (ALNY) Q3 2018 Earnings Conference Call Transcript", "Pre-Market Earnings Report for November 7, 2018 : FOXA, SO, HUM, SRE, ROK, GIB, CNHI, ALNY, ANDX, KORS, COTY, CDK", "Noteworthy Friday Option Activity: GE, ALNY, CBM", "Tenet Healthcare (THC) Q3 Earnings: What's in the Cards?", "Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?", "Regeneron (REGN) to Report Q3 Earnings: Is a Beat in Store?", "Here's Why Alnylam Pharmaceuticals Crashed 11.9% on Wednesday", "Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release", "What's in the Cards for AbbVie (ABBV) This Earnings Season?", "Molina Healthcare's (MOH) Q3 Earnings: Is a Beat in Store?", "The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals", "5 Drug/Biotech Stocks Likely to Beat Estimates in Q3 Earnings", "Is a Beat in Store for Zoetis (ZTS) This Earnings Season?", "Alexion (ALXN) to Report Q3 Earnings: What's in the Cards?", "What's in the Cards for Novavax (NVAX) This Earnings Season?", "J&J Inks Deal With Arrowhead for Promising Liver Candidate", "Health Care Sector Update for 10/04/2018: ACST,ACST.V,ALNY,TLRY", "Health Care Sector Update for 10/04/2018: MNK,PX,ACST,ACST.V,ALNY,TLR", "Alnylam Files Clinical Trial Application for ALN-AAT02 in UK", "Health Care Sector Update for 10/04/2018: ACST,ALNY,TLRY", "Medicines Company to Continue Inclisiran Studies as Planned", "Here's Why Alynlam Pharmaceuticals is Hogging the Limelight", "Alnylam to Pursue Full Approval & Rolling NDA for Givosiran", "Health Care Sector Update for 09/14/2018: ARGX,CSBR,ALNY", "Wednesday's ETF with Unusual Volume: XT", "Noteworthy Monday Option Activity: ALNY, ACOR, EROS", "Here's Why Dicerna Pharmaceuticals, Inc. Is on a Roller Coaster; Down 18% Yesterday, Up 17% Today", "7 Lucrative Biotech Stocks With Up to 300% Upside", "Thursday's ETF with Unusual Volume: IYH", "BBH's Holdings Imply 12% Gain Potential", "Health Care Sector Update for 09/14/2018: KALV, ARGX,CSBR,ALNY", "Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe", "Alnylam Gets European Nod for First-Ever RNAi Therapeutic", "Can Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. Recover?", "Pfizer's Tafamidis Fails to Impress in Cardiomyopathy Study", "6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug", "Monday's ETF Movers: FBT, XLU", "Alnylam Pharmaceuticals (ALNY) Shares Cross Above 200 DMA", "Alnylam's Shares Up as Onpattro Gets FDA and EU Approvals", "Notable Monday Option Activity: AMCX, ALNY, TTPH", "Here's Why Alnylam Pharmaceuticals and Ionis Pharmaceuticals Jumped Today", "2 Blockbuster New Drug Launches Making Investors Nervous Right Now", "Biotech Stock Roundup: Label Expansion of Regeneron's Eylea, Vertex's Kalydeco", "Alnylam Completes Enrollment in Phase III Givosiran Study", "Should Alnylam's and Ionis' Investors Be Worried About This Recent IPO?", "3 Things Alnylam's Management Wants Investors to Know About the Launch of Onpattro", "What Happened in the Stock Market Today", "Here\u2019s Why Alnylam\u2019s Shares Are Tumbling", "2 Reasons Alnylam Stock Fell on a Landmark Drug Approval", "3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug", "Akcea Therapeutics Soars as It Readies Its First Drug Launch", "Commit To Buy Alnylam Pharmaceuticals At $60, Earn 10.3% Using Options", "Alnylam (ALNY) Gets FDA Nod for First-Ever RNAi Therapeutic", "What Happened in the Stock Market Today", "3 Tough-Luck Tumbles in Healthcare: Are They Buys?", "7 Biotech Stocks With Big Upcoming Catalysts", "Alnylam's (ALNY) Q2 Loss Wider Than Expected, Sales Beat", "Alnylam Pharmaceuticals (ALNY) Q2 2018 Earnings Conference Call Transcript", "Alnylam Pharmaceuticals Is \"Launch Ready\"", "Noteworthy Friday Option Activity: ALNY, URBN, AOBC", "Medicines Company (MDCO) Q2 Loss Narrows, Revenues Tank Y/Y", "We Did The Math SPLG Can Go To $36", "Notable Monday Option Activity: ALNY, UNH, JKHY", "Drug Stock Q2 Earnings Releases on Aug 2: ZTS, REGN & More", "Why Arrowhead Pharmaceuticals, Inc. Stock Slumped Today", "Is Ionis Pharmaceuticals, Inc. a Buy?", "Regulus Stock Plunges on Cash Concerns Despite Restructuring", "Surprising Analyst 12-Month Target For EQAL", "Sanofi's Blood Clotting Drug Gets Positive CHMP Opinion", "Medicines Company's Inclisiran Studies to Continue Unmodified", "Earnings Reaction History: Alnylam Pharmaceuticals Inc., 42.9% Follow-Through Indicator, 7.1% Sensitive", "Health Care Sector Update for 06/08/2018: ALNY, NVS, MYOV, BTX, TROV", "Health Care Sector Update for 06/08/2018: ADMA,TROV,ALNY,NVS", "Health Care Sector Update for 06/08/2018: TROV, ALNY, NVS", "3 Top Biotech Stocks to Buy in June", "3 Strong Buy Stocks Trading at Steep Discounts", "Why Is Alnylam (ALNY) Up 12.6% Since Its Last Earnings Report?", "Better Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam Pharmaceuticals, Inc.", "Alnylam Reports Positive Data on Lumasiran in Renal Disease", "Health Care Sector Update for 06/08/2018: ALNY, NVS, MYOV, BTX, TROV", "Health Care Sector Update for 06/08/2018: ADMA,TROV,ALNY,NVS", "Health Care Sector Update for 06/08/2018: TROV, ALNY, NVS", "First Week of ALNY May 18th Options Trading", "Ionis Pharmaceuticals Prepares for Launch", "Alnylam Looks Forward", "Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss", "BBH's Holdings Could Mean 24% Gain Potential", "Analysts Predict 13% Gains Ahead For The Holdings of IWB", "Medicines Company's (MDCO) Q1 Loss Widens, Revenues Tank Y/Y", "Health Care Sector Update for 04/23/2018: DRNA,ALNY,HSIC,BHVN,AKRX,FMS", "Why Dicerna Rocketed Higher Today", "Alnylam (ALNY) Reports Positive Data for RNAi Candidate", "EMA Accepts Regeneron/Sanofi's application for Dupixent", "How Worried Should Alnylam and Ionis Really Be About Pfizer's New Data?", "RSI Alert: Alnylam Pharmaceuticals (ALNY) Now Oversold", "Oversold Conditions For Alnylam Pharmaceuticals (ALNY)", "Monday's ETF Movers: GDXJ, FBT", "Alnylam Pharmaceuticals (ALNY) Shares Cross Below 200 DMA", "Why Pfizer's Big Win Is Bad News for Alnylam and Ionis", "Pfizer's Rare Disease Candidate Meets Endpoint in Phase III", "Alnylam Falls on Pfizer's Rare Disease Drug Success", "Add Up The Parts: ACWI Could Be Worth $82", "Why Alnylam Pharmaceuticals, Inc. Is Tanking Today", "3 Blockbuster Drug Launches to Watch In 2018", "Gilead Sciences' Investors Better Watch This Regeneron-Alnylam Deal", "Is Ionis Pharmaceuticals, Inc. a Buy?", "SPDR S&P Biotech ETF Experiences Big Inflow", "Regeneron Collaborates With Alnylam to Develop NASH Treatment", "Better Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam", "ALNY Crosses Above Average Analyst Target", "Notable Thursday Option Activity: WYNN, BA, ALNY", "Alnylam Pharmaceuticals (ALNY) Up 1.6% Since Earnings Report: Can It Continue?", "Why Tesla, Oclaro, and Alnylam Pharmaceuticals Jumped Today", "Health Care Sector Update for 03/12/2018: SRPT,BIIB,PFE,SVRA,ALNY,SNY", "Health Care Sector Update for 03/12/2018: SVRA,ALNY,SNY", "Notable Friday Option Activity: MS, ETFC, ALNY", "New Strong Sell Stocks for March 6th", "Why Investors Are Paying a Premium For These 3 Biotech Stocks", "Health Care Sector Update for 03/12/2018: SVRA, SRPT, ALNY, REGN, SNY, BIIB, PFE", "Is Alnylam Pharmaceuticals, Inc. a Buy?", "Medicines Company (MDCO) Reports Q4 Loss, Revenues Slump Y/Y", "Alnylam Pharmaceuticals Starts the Wait for Approval", "Alnylam's (ALNY) Q4 Earnings and Revenues Top Estimates", "The Math Shows VOT Can Go To $142", "3 Top Cholesterol Drug Stocks to Consider Buying Now", "Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review", "Commit To Buy Alnylam Pharmaceuticals At $90, Earn 12.2% Using Options", "Why The Medicinces Company Is Having an Outstanding Week", "Why 2017 Was a Year to Remember for Ionis Pharmaceuticals, Inc.", "Sanofi to Acquire Haemophilia Focused Bioverativ, Stock Dips", "Prothena (PRTA) Tumbles 18% in a Year: What Lies Ahead?", "Three Interviews From the J.P. Morgan Healthcare Conference", "Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?", "Will 2018 Be Ionis Pharmaceuticals, Inc.'s Best Year Yet?", "Sanofi on a Buyout Spree This Month, to Buy Ablynx for $4.8B", "Why The Medicinces Company Is Having an Outstanding Week", "Why 2017 Was a Year to Remember for Ionis Pharmaceuticals, Inc.", "Sanofi to Acquire Haemophilia Focused Bioverativ, Stock Dips", "Notable ETF Inflow Detected - VB, ALNY, CGNX, CSGP", "3 Top Value Stocks to Buy in 2018", "5 of the Best-Performing Biotech Stocks of 2017", "4 Biotech Stocks That More Than Doubled This Year", "This Is Why Alnylam Pharmaceuticals Soared 249% in 2017", "Regeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab", "Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy", "Alnylam/Sanofi Submit MAA in Europe for RNAi Candidate", "Sanofi/Alnylam Say FDA Lifts Clinical Hold on Fitusiran", "The FDA Just Blessed A Hemophilia Trial From This Biotech", "Health Care Sector Update for 12/15/2017: JNJ, PFE, ABT, MRK, AMGN, ALNY, NVO, SGRY, RIGL, TEVA", "Notable ETF Outflow Detected - VBK, ALNY, CGNX, XPO", "VBK, TTWO, CGNX, ALNY: ETF Inflow Alert", "Why Alnylam Pharmaceuticals Rose 12.7% in November", "Notable ETF Inflow Detected - XBI, ALNY, JUNO, SRPT", "ALNY Crosses Above Average Analyst Target", "Why Medicines Co. Is Tumbling Despite $270 Million Deal", "Here's How Alnylam Pharmaceuticals, Inc. Crushed It in 2017", "Commit To Buy Alnylam Pharmaceuticals At $70, Earn 11.4% Using Options", "Alnylam Gets Some Welcome News", "Opus Point Partners Management, LLC Buys Bioverativ Inc, ACADIA Pharmaceuticals Inc, United ...", "Alnylam Starts Rolling NDA Submission for RNAi Candidate", "Why is Alnylam's (ALNY) Stock Up More Than 200% this Year?", "SPDR S&P Biotech ETF Experiences Big Outflow", "Health Care Sector Update for 11/16/2017: ALNY", "Alnylam Pharmaceuticals, Inc.'s Pipeline Progresses, Approval Next", "Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA", "Alnylam's RNAi Candidate Gains Breakthrough Therapy Status", "Ionis Pharmaceuticals Inc. Sets Itself Up for Growth", "Ionis Pharmaceuticals' Earnings Results Fuel Volatility", "Alnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates", "How to Invest in Biotech Stocks", "Noteworthy ETF Inflows: XBI, ALNY, PBYI, SGEN", "After-Hours Earnings Report for November 7, 2017 : MAR, ETP, ETE, CLR, AGU, ALNY, XEC, TTWO, DVA, JKHY, JAZZ, PPC", "What's in Store for Catalyst (CPRX) This Earnings Season?", "Pre-Market Most Active for Nov 14, 2017 : BNDX, ROKU, DKS, HMC, GE, TVIX, PHG, GOLF, JD, HD, QQQ, ALNY", "What's in Store for Ligand (LGND) This Earnings Season?", "What's in Store for Madrigal (MDGL) This Earnings Season?", "Inovio (INO) Q3 Earnings: Is a Beat in Store for the Stock?", "Ionis Rebounds After Beating Alnylam To Drug Application In Europe", "Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 10.3% in Session", "Alnylam Spikes \u2014 Prodding Ionis' Pitfall \u2014 On Rare-Disease Drug Trial", "Here's Why Alnylam's Gain Is Ionis Pharmaceuticals' Loss Today", "Is a Surprise Coming for Alnylam Pharmaceuticals (ALNY) This Earnings Season?", "Biotechs Lead Health Sector, But Are Those Glory Days Over?", "How Celgene, Gilead's Pricing Woes Continue To Haunt Biotech Stocks", "Medicines Company (MDCO) Reports Q3 Loss, Revenues Miss", "XBI, ALNY, CLVS, SGEN: ETF Outflow Alert", "SPDR S&P Biotech ETF Experiences Big Outflow", "XLF, FNY: Big ETF Inflows", "Here's Why Alnylam Pharmaceuticals Rallied 32.7% in September", "XBI, ALNY, PBYI, SGEN: ETF Inflow Alert", "Analysts Act on Health Care Stocks", "3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?", "Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up", "Company News For Sep 21, 2017", "Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 51.7% in Session", "Wednesday's ETF with Unusual Volume: FNX", "What's Next for Alnylam Pharmaceuticals, Inc.?", "FXH, ALNY, ALGN, GILD: Large Inflows Detected at ETF", "Calamities Couldn't Spoil The Bullish Run", "Hurricanes, Earthquakes and Record-High Markets", "Mid-Morning Market Update: Markets Edge Lower; General Mills Earnings Miss Estimates", "Pre-Market Most Active for Sep 20, 2017 : NBRV, FWONK, BBBY, ALNY, CHU, RAD, DB, MU, WDC, TEVA, S, BBU", "What Happened in the Stock Market Today", "Here's Why Arbutus Biopharma Corp. Stock Soared Today", "Close Update: Dow, S&P 500 Hit Records as Wobbly Session Sees Financials Gain After Fed", "Mid-Day Market Update: Bed Bath & Beyond Drops On Earnings Miss; DelMar Pharmaceuticals Shares Plunge", "Calamities Couldn't Spoil The Bullish Run", "Hurricanes, Earthquakes and Record-High Markets", "Mid-Morning Market Update: Markets Edge Lower; General Mills Earnings Miss Estimates", "Billionaire George Soros' Fund Bought These 3 Pharma Stocks: Should You?", "Notable Friday Option Activity: ALNY, CVA, TWTR", "Alnylam Shares Plunge on Patient Death, Dosing Suspended", "Here's Why Alnylam Pharmaceuticals, Inc. Is Slipping Today", "Mid-Afternoon Market Update: Crude Oil Up Over 2%; Alnylam Pharma Shares Climb After Positive Phase 3 Results", "Pre-Market Most Active for Sep 7, 2017 : CAB, BLDR, GPRO, TVIX, IRT, GE, INSM, AZN, WLL, BAC, ALNY, QQQ", "What Happened in the Stock Market Today", "Health Care Sector Update for 09/07/2017: SGRY,NLNK,ALNY", "Health Care Sector Update for 09/07/2017: EKSO, NLNK, ALNY", "Noteworthy Wednesday Option Activity: PII, ALNY, GPI", "4 Biotech Stocks That More Than Doubled This Year", "ALNY Crosses Above Average Analyst Target", "Morning Movers: Barnes & Noble Sinks on Earnings; Hertz Jumps", "The Medicines Co's Inclisiran Positive in Extension Study", "Sangamo Therapeutics Initiates Dosing in Hemophilia A Study", "3 Biotech Stocks That Could Soar in September", "Monday's ETF with Unusual Volume: BBH", "Ionis Pharmaceuticals Retains Rights to Inotersen, Stock Up", "Alnylam Pharmaceuticals, Inc. Earnings: Waiting for Apollo", "Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs", "4 Biotech Stocks That More Than Doubled This Year", "The Medicines Company (MDCO) Q2 Loss Widens, Revenues Miss", "After-Hours Earnings Report for August 9, 2017 : NTES, MFC, FOXA, SLF, AGU, LYV, UHAL, ALNY, MIDD, GXP, RGLD, CSRA", "3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings", "Arena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected", "Why Alnylam Pharmaceuticals (ALNY) Might Surprise This Earnings Season", "Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View", "Endo (ENDP) Beats Q2 Earnings & Sales, 2017 Guidance Lowered", "Alnylam (ALNY) Q2 Loss Narrower than Expected, Sales Miss", "Alnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth", "Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data", "Alnylam Commences Phase III Study for Hemophilia Candidate", "Are Medicines Company's Key Drugs Set for Growth in 2017?", "Alnylam Pharmaceuticals, Inc. Stock Perked Up 14% in June -- Here's Why", "Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod", "3 Pivotal Drug Trials to Watch for Explosive Potential", "ALNY Crosses Above Average Analyst Target", "5 Best Biotech Stocks of 2017 So Far", "Why is Alnylam's (ALNY) Stock Close to 100% this Year?", "Alnylam Still Has A Lot Of Upside: Bhavneesh Sharma's Idea Of The Month", "Why Is Alnylam (ALNY) Up 31.2% Since the Last Earnings Report?", "Thursday 6/1 Insider Buying Report: PBF, ALNY", "Alnylam's Givosiran Gets Breakthrough Therapy Status by FDA", "Commit To Buy Alnylam Pharmaceuticals At $50, Earn 18% Annualized Using Options", "5 Biotech Stocks With Major Catalysts in July", "Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline", "Pre-Market Most Active for May 24, 2017 : NOW, FGL, GLYC, FCAU, INO, LOW, STNG, BAC, NVDA, TTD, QQQ, ALNY", "Alnylam Pharmaceuticals Reaches Analyst Target Price", "Alnylam Pharmaceuticals (ALNY) Looks Good: Stock Jumps 16.3%", "Why Ionis Pharmaceuticals Inc Tanked and Alnylam Pharmaceuticals, Inc. Is Soaring Today", "Noteworthy Monday Option Activity: AAP, WLB, ALNY", "Pre-Market Most Active for May 15, 2017 : PTHN, SAN, BP, NOK, SNAP, STM, FEYE, IONS, AAPL, TSLA, ALNY, JIVE", "Regeneron Presents Positive Phase II Data on HoFH Candidate", "Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline", "Health Care Sector Update for 05/05/2017: ALNY", "Earnings Reaction History: Alnylam Pharmaceuticals Inc., 40.0% Follow-Through Indicator, 7.6% Sensitive", "Pre-Market Earnings Report for May 5, 2017 : CI, TRP, CTSH, HCN, MCO, CNP, BPL, JLL, SNH, CFX, ALNY, VWR", "The Medicines Company (MDCO) Q1 Loss Wider Than Expected", "ALNY Makes Bullish Cross Above Critical Moving Average", "5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now", "Alnylam Pharmaceuticals, Inc. Earnings: All Eyes on APOLLO", "5 Deadliest Diseases in the U.S. -- and the Top Drugs Potentially on the Way to Treat Them", "The 3 Best Cholesterol Drug Stocks to Buy in 2017", "How This Company Is Taking on Amgen", "Alnylam (ALNY) Up 14.5% Since Earnings Report: Can It Continue?", "Alnylam's LDL-Lowering Drug Positive in Phase II Study", "Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals", "Here's Why Alnylam Pharmaceuticals, Inc. Stock Bounced Up 10.1% Today", "Regeneron's Evinacumab Gets Breakthrough Therapy by FDA", "FBT, ACAD, ALNY, KITE: ETF Outflow Alert", "Better Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc.", "Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise", "Thursday's ETF Movers: XBI, GDX", "Alnylam Pharmaceuticals, Inc. Presents Progress -- Investors Dig It", "Better Buy: Agenus Inc. vs. Alnylam Pharmaceuticals, Inc.", "Why The Medicines Company Rocketed Higher Today", "Commit To Purchase Alnylam Pharmaceuticals At $35, Earn 20.9% Annualized Using Options", "Mid-Afternoon Market Update: Derma Sciences Climbs On Acquisition News; Novadaq Shares Plunge", "Wednesday's ETF Movers: OIH, XBI", "Wednesday Sector Laggards: Drugs, Biotechnology Stocks", "The Medicines Co LDL-Lowering Drug Positive in Phase II", "Why Alnylam Pharmaceuticals, Inc. Stock Is a 2017 Winner (ALNY)", "Here's Why Alnylam Pharmaceuticals Plunged 59.8% in 2016", "A Winning Pharmaceutical Stock For 2017", "The Implied Analyst 12-Month Target For PBE", "Better Buy: Alnylam Pharmaceuticals vs. Ionis Pharmaceuticals", "Why Cliffs Natural Resources, Groupon, and Alnylam Pharmaceuticals Slumped Today", "Better Buy: Juno Therapeutics vs. Alnylam Pharmaceuticals", "2 Reasons Why Alnylam Pharmaceuticals Stock Gained 18.5% in November", "3 Things You Need to Know About Ionis Pharmaceuticals' Pipeline", "Commit To Buy Alnylam Pharmaceuticals At $35, Earn 19.1% Using Options", "Analysts Forecast 20% Gains Ahead For The Holdings of FBT", "Health Care Sector Update for 01/06/2017: MDCO, SNY, REGN, JNJ, PFE, ABT, MRK, AMGN", "Why These Biotechs Saw Double-Digit Gains Today", "Why Alnylam Pharmaceuticals, Inc. Took a 47.5% Dive in October", "Alnylam Pharmaceuticals, Inc. Discloses Deaths, Waits for More Data", "Friday's ETF with Unusual Volume: BBH", "Alnylam (ALNY) Q3 Loss Wider than Expected, Revenues Up", "Alnylam Pharmaceuticals Slid 12.6% Today After Earnings", "The Medicines Co. Reports Positive Phase II Data on PCSK9si", "Sanofi Opts into Alnylam's Fitusiran Hemophilia Program in U.S.", "Surprising Analyst 12-Month Target For FBT", "Alnylam (ALNY) to Continue Phase III Study on Patisiran", "Biotech Stock Roundup: Alnylam Slumps on Revusiran Update, TESARO Impresses at ESMO", "Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc.", "Kamada (KMDA) Extends Partnership with Shire for Glassia", "What's Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure?", "Alnylam's RNAi Failure Could Catch Monsanto Investors Off Guard", "Monday 10/17 Insider Buying Report: ALNY, RHP", "Mid-Morning Market Update: Markets Open Lower; Yum! Brands Sales Miss Estimates", "Why Alnylam Pharmaceuticals Is Getting Crushed Today", "Alnylam (ALNY) Discontinues Phase III Study on Revusiran", "Pre-Market Most Active for Oct 6, 2016 : TWTR, KLAC, AUPH, SNY, CRM, ALNY, RDS/B, NOK, LRCX, WMT, MDCO, JD", "Health Care Sector Update for 10/06/2016: PFE,PHMD,ALNY", "Mid-Afternoon Market Update: Crude Oil Up 1.5%; Alnylam Pharma Shares Tumble On Revusiran Termination", "Health Care Sector Update for 10/06/2016: SCYX, PHMD, ALNY, SLRC", "Mid-Day Market Update: Aurinia Pharmaceuticals Gains On AURION Data; Twitter Shares Slide", "Mid-Day Market Update: Crude Oil Rises Over 2%; Intra-Cellular Therapies Shares Slide", "Mid-Morning Market Update: Markets Edge Lower; PepsiCo Beats Q3 Expectations", "Better Buy: Ziopharm Oncology, Inc. vs. Alnylam Pharmaceuticals, Inc.", "3 Ways Ionis Pharmaceuticals, Inc. Is Beating the Competition", "Alnylam (ALNY) Reports Positive Phase I Data on ALN-AS1", "Better Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals", "Notable Monday Option Activity: SRPT, ALNY, SWFT", "Why The Medicines Company's Share Price Got Sick Today", "Alnylam Pharmaceuticals (ALNY) Shares March Higher, Can It Continue?", "Alnylam Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ALNY", "Why Alnylam Pharmaceuticals, Inc. Stock Gained 10.8% in July", "Earnings Reaction History: Alnylam Pharmaceuticals Inc., 50.0% Follow-Through Indicator, 6.1% Sensitive", "5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More", "7 Biotech Stocks With Pivotal Catalysts in 2017", "Health Care Sector Update for 07/25/2016: ALNY,BIND,TBRA", "Alnylam Pharmaceuticals, Inc. Cranks Out the Data", "U.S. Stocks Extend Gains Following Better-Than-Expected Jobs Report", "Better Buy: Alnylam Pharmaceuticals, Inc. vs. Incyte", "Alnylam Stock Up on Favorable Patisiran and Revusiran Data", "Better Buy: Ionis Pharmaceuticals vs. Alnylam Pharmaceuticals", "Why Alnylam Pharmaceuticals, Inc. Is Down 37.3% This Year", "Why Alnylam Pharmaceuticals, Inc. Jumped 10.7% on Friday", "3 Biotech Stocks to Buy in July", "Alnylam (ALNY) Begins Phase I/II Study on Chronic HBV Drug", "Could Alnylam Pharmaceuticals Change Medicine as We Know It?", "Ionis Down, Glaxo Dumps IONIS-TTRRx Phase III Study Plans", "Alnylam Pharmaceuticals (ALNY) in Focus: Stock Rises 9.9%", "Why Alnylam Pharmaceuticals, Inc. Competed Higher Today", "Better Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals Inc.", "Drawing Biopharma Concepts With A Crayon", "VIVUS (VVUS) Q1 Loss Narrower but Qsymia Sales Decline", "FBT's Underlying Holdings Could Mean 28% Gain Potential", "Alnylam Pharmaceuticals, Inc.'s Double-Digit \"Earnings\" Fall", "Alnylam (ALNY) Reports Wider-than-Expected Loss in Q1", "Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta", "After-Hours Earnings Report for May 2, 2016 : AIG, APC, GGP, EIX, VNO, SBAC, EXR, UGI, ARE, AFG, FMC, ALNY", "Regeneron's Bold Bet on the Future of Medicine", "How The Pieces Add Up: IYH Targets $170", "Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals", "Noteworthy Wednesday Option Activity: ALNY, ZG, SCTY", "BioMarin (BMRN) BMN 270 Gets Orphan Drug Status in EU", "Bayer's Kovaltry Gets Approval in the U.S. for Hemophilia A", "Alnylam Director buys 2,000 shares", "Alnylam Begins Study for Primary Hyperoxaluria Type 1", "Can Conatus (CNAT) Surprise Estimates in Q4 Earnings?", "Better Buy: Juno Therapeutics vs. Alnylam Pharmaceuticals", "Why bluebird bio Inc, Juno Therapeutics Inc, and Alnylam Pharmaceuticals, Inc. Jumped Today", "Thursday's ETF Movers: FBT, KRE", "BioMarin (BMRN) BMN 270 Gets Orphan Drug Status in EU", "Bayer's Kovaltry Gets Approval in the U.S. for Hemophilia A", "Alnylam Director buys 2,000 shares", "Alnylam Pharmaceuticals, Inc.'s Most Important Slide", "Alnylam Provides Update on RNAi Therapeutics Pipeline", "Behind Alnylam Pharmaceuticals' December Plunge", "Alnylam Pharmaceuticals, Inc.: Waiting on APOLLO", "Alnylam Initiates Final Part of Phase I/II Study on ALN-CC5", "Noteworthy Thursday Option Activity: GLNG, ELLI, ALNY", "Will 2016 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?", "Alnylam Pharmaceuticals is Selling Off Today -- But Why?", "Alnylam Pharmaceuticals' Stock Picked Up Steam in November: Any Upside Remaining?", "First Week of ALNY January 2016 Options Trading", "November's Best Sector ETFs", "Alnylam Submits Clinical Trial Application for ALN-GO1 in UK", "Weekly Insider Sells Highlights: Facebook, PacWest Bancorp, Waste Management, Alnylam ...", "Alnylam Pharmaceuticals, Inc. Earnings: 100% Positive (Data)", "These 2 Companies Could Revolutionize Heart Disease Prevention", "Alnylam (ALNY) Reports Positive Interim Data on ALN-PCSsc", "Alnylam Q3 Loss Narrower than Expected, Revenues Miss", "Alnylam Pharmaceuticals (ALNY) Shares Cross Above 200 DMA", "Is Intrexon (XON) Likely to Disappoint This Earnings Season?", "These 3 Biotechs Are Winning in the Clinic", "Will Puma Biotechnology (PBYI) Surprise in Q3 Earnings?", "Will Merrimack (MACK) Surprise Estimates in Q3 Earnings?", "Will Intercept (ICPT) Beat Estimates in Q3 Earnings?", "Catalyst Pharmaceutical (CPRX): A Peek into Q3 Earnings", "Will Inovio (INO) Disappoint Investors this Earnings Season?", "Will BioDelivery (BDSI) Disappoint Estimates in Q3 Earnings?", "What's in Store for Repros (RPRX) this Earnings Season?", "Pre-Market Earnings Report for November 9, 2015 : PCLN, DISH, AMG, ALNY, WWAV, ISIS, COMM, SNI, ICPT, HPT, NRF, NSAM", "Horizon (HZNP): What's in Store this Earnings Season?", "Will Agios (AGIO) Disappoint Investors this Earnings Season?", "Synta (SNTA) Q3 Earnings Preview: What's in the Cards?", "Can Endo International's (ENDP) Q3 Earnings Surprise?", "Will AVEO (AVEO) Pull a Surprise this Earnings Season?", "What's in Store for Conatus (CNAT) this Earnings Season?", "What to Expect from Radius (RDUS) This Earnings Season", "Celgene (CELG) to Report Q3 Earnings: What to Expect?", "What's in Store for Regeneron (REGN) This Earnings Season?", "What's in the Cards for Zoetis (ZTS) this Earnings Season?", "Health Care Sector Update for 10/23/2015: CYAD, RARE, ALNY", "Alnylam Offers Data on ALN-TTRsc02 & Platform Technology", "Health Care Sector Update for 10/13/2015: ALNY,IMNP,HTWR", "Alnylam Initiates Extension Study on ALN-AT3 for Hemophilia", "Sanofi Opts into Alnylam's ALN-AT3 Hemophilia Program", "What's in Store for Endocyte (ECYT) This Earnings Season?", "First Week of ALNY November 20th Options Trading", "Alnylam Reports Positive Initial Phase I Data on ALN-AS1", "Alnylam to Speed Up Development for Primary Hyperoxaluria", "PCSK9 Drugs Are Here (and Way Over There)", "The Zacks Analyst Blog Highlights: Amgen, ARIAD, Celgene, Amicus and Alnylam", "Biotech Stock Roundup: Amgen in the News, ARIAD a Takeover Target?", "Alnylam Pharmaceuticals (ALNY) Falls: Stock Goes Down 5.7%", "Alnylam's Extension Study on Patisiran Reveals Positive Data", "First Week of October 16th Options Trading For Alnylam Pharmaceuticals (ALNY)", "Health Care Sector Update for 08/31/2015: ALNY, MDCO, BLFS, FOLD", "Alnylam Presents Positive Data on PCSK9 Synthesis Inhibitor", "Here's Why Alnylam Pharmaceuticals' Stock Crashed Today", "ALNY Crosses Below Key Moving Average Level", "Alnylam's Q2 Loss Wider than Expected, Revenues Fall Short - Analyst Blog", "After-Hours Earnings Report for August 6, 2015 : EOG, MNST, ED, MHK, NVDA, ALNY, PBA, MDVN, ANAC, NUAN, ANET, LGF", "Why The Medicines Company's Stock Broke Out Today", "First Week of October 16th Options Trading For Alnylam Pharmaceuticals (ALNY)", "Health Care Sector Update for 08/31/2015: ALNY, MDCO, BLFS, FOLD", "Alnylam Reports Encouraging New Data on Hemophilia Drug - Analyst Blog", "Insiders Seeing Green With ALNY At New 52-Week High", "Alnylam Reveals Positive Initial Data on RNAi Drug ALN-CC5 - Analyst Blog", "Health Care Sector Update for 06/11/2015: DRNA,ALNY,MRK,PTBI,PBMD", "First Week of March 2016 Options Trading For Alnylam Pharmaceuticals (ALNY)", "Health Care Sector Update for 06/11/2015: AXON,DRNA,ALNY,PTBI", "Why Shares in Regulus Therapeutics Inc. Are Tumbling", "Alnylam (ALNY) Begins Phase I Study on Liver Disease Drug - Analyst Blog", "Alnylam's Cardiac Amyloidosis Drug Gets Orphan Status - Analyst Blog", "Alnylam Files Clinical Trial Application for ALN-AAT - Analyst Blog", "Alnylam's Q1 Loss Narrower than Expected, Confirms Guidance - Analyst Blog", "Alnylam Pharmaceuticals, Inc.'s Five-Year Plan", "Use Options For a Chance To Buy ALNY at a 35% Discount", "3 Biotech Stocks Still Attractive After Monday's Sell-Off - Analyst Blog", "Use Options For a Chance To Buy ALNY at a 32% Discount", "The Zacks Analyst Blog Highlights: Amgen, Medicines, Athersys and Alnylam - Press Releases", "Can the Rally in Alnylam Pharmaceuticals (ALNY) Shares Continue? - Tale of the Tape", "Alnylam Reports Positive Patisiran Results, Shares Up - Analyst Blog", "Biotech Stock Roundup: Amgen Starts Earnings Season on Strong Note, Setbacks for Ampio & Athersys - Analyst Blog", "Why Alnylam Pharmaceuticals, Inc. Shares Are Soaring Today", "The Zacks Analyst Blog Highlights: Celladon, Amgen, Biogen and Alnylam Pharmaceuticals - Press Releases", "Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick - Tale of the Tape", "Infinity Pharmaceuticals Exercises Duvelisib Royalty Option - Analyst Blog", "Hospira Presents Data on Retacrit, an Epogen Biosimilar - Analyst Blog", "Interesting ALNY Put And Call Options For May 15th", "Use Options For a Chance To Buy ALNY at a 30% Discount", "3 Biotech Stocks to Buy If the Sector Crashes", "Alnylam Announces Positive Data from Natural History Study - Analyst Blog", "Alnylam Reports Publication of New Data on Hemophilia Drug - Analyst Blog", "Vanda Down after Candidate Disappoints in Phase II Study - Analyst Blog", "Mylan Beats on Q4 Earnings, 2015 Guidance Encouraging - Analyst Blog", "QLT (QLTI) Reports Wider Year-over-Year Loss in Q4 - Analyst Blog", "Endo (ENDP) Beats Q4 Earnings, Announces Divestments - Analyst Blog", "Amgen's Kyprolis Fares Better than Velcade in Study - Analyst Blog", "Whoa, a Profit for Isis Pharmaceuticals Inc.", "Aegerion's Q4 Loss Narrows Y/Y, Ups Juxtapid Sales View - Analyst Blog", "Alnylam (ALNY) Shares March Higher, Can It Continue? - Tale of the Tape", "Pharmacyclics Misses on Q4 Earnings, Reiterates 2015 View - Analyst Blog", "Theravance Reports In Line Loss in Q4, Revenues Increase - Analyst Blog", "Company News for February 17, 2015 - Corporate Summary", "Actelion's (ALIOF) Earnings & Revenues Fall Y/Y in Q4 - Analyst Blog", "Hospira Launches Inflectra, Remicade Biosimilar, in Europe - Analyst Blog", "Emergent BioSolutions Reports Positive Data on BioThrax - Analyst Blog", "2 Small Biotech Stocks Dreaming Big in Hepatitis C", "Use Options For a Chance To Buy ALNY at a 36% Discount", "Incyte Posts Wider-than-Expected Q4 Loss; Revenues Miss - Analyst Blog", "Alnylam Reports Narrower Loss in Q4, Focuses on Pipeline - Analyst Blog", "Hospira Beats on Q4 Earnings, Set to Be Acquired by Pfizer - Analyst Blog", "Loaded-Up Alnylam Pharmaceuticals, Inc. Progresses Its Pipeline", "After-Hours Earnings Report for February 12, 2015 : AIG, KRFT, CBS, DVA, RSG, DLR, ALNY, SSNC, GRPN, TCO, EGN, AIZ", "Zoetis Beats on Q4 Earnings, Provides In-Line 2015 Outlook - Analyst Blog", "Celgene Up on Abraxane Getting Positive Recommendation - Analyst Blog", "Zacks Rank #1 Additions for Friday - Tale of the Tape", "Regeneron Beats on Q4 Earnings Driven by Eylea Sales - Analyst Blog", "Orexigen Gives Positive Updates on its Weight Loss Drug - Analyst Blog", "What's in Store for Acadia Healthcare (ACHC) this Earnings? - Analyst Blog", "Why Earnings Season Could Be Great for Alnylam Pharmaceuticals (ALNY) - Tale of the Tape", "AstraZeneca plc Beefs Up Precision Medicine Arsenal", "Will Kforce (KFRC) Earnings Surprise on Improving Business? - Analyst Blog", "Will Republic Services (RSG) Surprise on Q4 Earnings This Season? - Analyst Blog", "Synthetic Biologics Unveils Phase Ib Safety Data on SYN-004 - Analyst Blog", "Can Gilead Boost HCV Sales with Health Service Deals? - Analyst Blog", "Can Cerner (CERN) Surprise Earnings Estimates in Q4? - Analyst Blog", "Perrigo Beats on Earnings, FY15 Guidance In Line - Analyst Blog", "Gilead Tops Q4 Earnings Estimates, 2015 Outlook Disappoints - Analyst Blog", "Why Isis Pharmaceuticals, Inc. Shares Exploded Higher By 11% in January", "Will Stericycle (SRCL) Q4 Earnings Beat on Organic Growth? - Analyst Blog", "Will Atmel (ATML) Surprise Q4 Earnings on Organic Growth? - Analyst Blog", "Will Alere (ALR) Surprise Earnings Estimates This Season? - Analyst Blog", "AbbVie Q4 Earnings Beat Expectations on Humira Strength - Analyst Blog", "Thursday 1/29 Insider Buying Report: ALNY, SSB", "Will Xerox (XRX) Disappoint Q4 Earnings This Season? - Analyst Blog", "Will International Paper (IP) Surprise on Q4 Earnings? - Analyst Blog", "First Week of September 18th Options Trading For Alnylam Pharmaceuticals (ALNY)", "Mid-Day Market Update: U.S. Stocks Surge; Netflix Shares Jump On Upbeat Earnings", "Will Restructuring Initiatives Drag Q4 Earnings of GE? - Analyst Blog", "Biogen Tops Q4 Earnings, Provides Strong Outlook for 2015 - Analyst Blog", "Pre-Market Most Active for Jan 21, 2015 : SUNE, UL, SNE, RBS, NFLX, ALNY, ARNA, MTU, TVIX, AAPL, BAC, QCOM", "Alnylam to Raise $450 Million Through Issuance of Shares - Analyst Blog", "Mid-Afternoon Market Update: Alnylam Pharmaceuticals Drops Following Equity Offering; Insperity Shares Spike Higher", "Health Care Sector Update for 01/20/2015: NBS, CPXX, ALNY", "Will China Woes Impact Amphenol (APH) Q4 Earnings? - Analyst Blog", "Should AbbVie Inc. Or Gilead Sciences Buy These Tiny Biotech Stocks?", "Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest", "Mid-Morning Market Update: Markets Mixed; UnitedHealth Profit Tops Expectations", "How These 3 Stocks Doubled Investors' Money in Q4", "How 1 Tiny Hepatitis C Drug Developer Trounced Gilead Sciences, Inc. in 2014", "Commit To Purchase Alnylam Pharmaceuticals At $65, Earn 12% Annualized Using Options", "Alnylam Provides Pipeline Update, Growth Strategy - Analyst Blog", "Alnylam Pharmaceuticals (ALNY) Shares March Higher, Can It Continue? - Tale of the Tape", "Alnylam Reports Positive Initial Phase I Data on ALN-AT3 - Analyst Blog", "Mid-Day Market Update: McDonald's Drops On Weak November Sales; Acceleron Pharma Shares Jump", "Health Care Sector Update for 01/09/2015: PTLA, TNXP, ISIS", "Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick - Tale of the Tape", "Regulus To See Further Declines", "Alnylam Reports Positive Initial Phase II Data on Revusiran - Analyst Blog", "Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog", "Isis Pharmaceuticals Inc. Strikes Out on Its Own", "Alnylam's Q3 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog", "Investing in Socially Responsible Companies: Alnylam Pharmaceuticals, Inc.", "Mid-Morning Market Update: Markets Mixed; Merck To Buy Cubist Pharmaceuticals For $102/Share", "Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog", "Will Humana (HUM) Miss on Earnings Estimates this Season? - Analyst Blog", "Will Actavis (ACT) Beat Earnings Estimates on Forest Deal? - Analyst Blog", "Is Hospira (HSP) Poised to Beat Q3 Earnings Estimates? - Analyst Blog", "Will Becton, Dickinson (BDX) Beat Q4 Earnings Estimates? - Analyst Blog", "Will IoT Market Focus Help Atmel (ATML) Beat Q3 Earnings? - Analyst Blog", "5 Best Biotech Stocks to Buy Now", "Alnylam Pharmaceuticals, Inc. Has This Ratio Right", "Alnylam Reveals Positive Data from its Pipeline Candidates - Analyst Blog", "Alnylam Pharmaceuticals (ALNY) Jumps: Stock Rises 19% - Tale of the Tape", "Alnylam Jumps on Positive Patisiran Data from Phase II Study - Analyst Blog", "Lithia Motors Dips On Lowered Earnings Forecast; CSX Shares Gain", "Markets Down; Targa To Acquire Atlas Pipeline, Atlas Energy", "U.S. Stocks Fluctuate; Shutterfly Shares Decline On Aborted Merger Talks", "Why Alnylam Pharmaceuticals Surged Higher", "Moving Average Crossover Alert: Alnylam Pharmaceuticals (ALNY) - Tale of the Tape", "Alnylam Reveals Positive Data from its Pipeline Candidates - Analyst Blog", "Alnylam (ALNY) to File Clinical Trial Application for ALN-CC5 - Analyst Blog", "Alnylam Expands Pipeline with Preeclampsia Drug ALN-AGT - Analyst Blog", "ALNY Makes Notable Cross Below Critical Moving Average", "Alnylam Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ALNY", "Alnylam's Q2 Loss Wider-than-Expected, Pipeline in Focus - Analyst Blog", "Sector Update: Health Care", "Alnylam Begins New Study on Hepatic Porphyrias Patients - Analyst Blog", "ALNY Crosses Below Key Moving Average Level", "Alnylam Up on Narrower-than-Expected Q1 Loss - Analyst Blog", "Sanofi Misses on Q1 Earnings, Lackluster Revs - Analyst Blog", "Thursday Sector Laggards: Biotechnology, Drugs", "Thursday's ETF Movers: THRK, XBI", "EPO Upholds Alnylam's McSwiggen Patent - Analyst Blog", "Sanofi, UCB Ink Deal - Analyst Blog", "Sector Update: Health-Care Shares Higher Pre-Market", "Sanofi/Ardelyx Ink Deal - Analyst Blog", "Bull of the Day: Alexion Pharma (ALXN) - Bull of the Day", "Alnylam Widens Q4 Loss - Analyst Blog", "iShares Russell 2000 ETF Experiences Big Inflow", "After-Hours Earnings Report for February 13, 2014 : AIG, KRFT, A, LBTYA, ALSN, ALNY, BRCD, IM, WRI, CGNX, CLF, WOOF", "Sanofi's Q4 Earnings Beat Overcast by Weak Guidance - Analyst Blog", "Gilead Beats on Earnings & Revs, Sovaldi off to a Flier - Analyst Blog", "Are These Biotechs Part of Your Portfolio? - Analyst Blog", "Pipeline Progress at Alnylam - Analyst Blog", "Orphan Drug Status for Alexion's Solaris - Analyst Blog", "Biotech Stock Roundup: Sarepta Spikes on Data & Alnylam on Deal - Analyst Blog", "Prospects Bright at Alexion Pharma - Analyst Blog", "Biotech Stock Roundup: Intercept Pharma Grabs the Limelight - Analyst Blog", "Company news for January 14, 2014 - Corporate Summary", "Alnylam Pharmaceuticals (ALNY) Soars: Stock Up 40.9% - Tale of the Tape", "Another Strong Earnings Beat from Amgen - Analyst Blog", "Mid-Day Market Update: SodaStream Drops After Weak Outlook; Beam Shares Spike Higher", "European Shares Rise on Easier Basel Regulations", "Mid-Morning Market Update: Markets Open Lower; Lululemon Lowers Q4 Outlook", "Pipeline Update at Alnylam - Analyst Blog", "Mid-Afternoon Market Update: Markets Dip Despite Large Amount of M&A", "Alnylam Pharmaceuticals, Inc. (ALNY): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report", "Pipeline Progress at Alnylam - Analyst Blog", "Alnylam Pharmaceuticals, Inc. (ALNY) Enters Overbought Territory - Tale of the Tape", "Biotech Stock Roundup: Vanda Soars, Sarepta Slumps - Analyst Blog", "Sector Update: Healthcare", "Sector Update: Healthcare Shares Mixed; CareFusion Agrees to Acquire General Electric", "Sector Update: Healthcare", "Wider-than-Expected Q3 Loss at Alnylam - Analyst Blog", "Healthcare Stocks Sliding into Close; Alynylam Pharma Sinks After Net Loss is Larger than Forecast", "Sector Update: Healthcare", "Alnylam Earns Milestone Payment - Analyst Blog", "Pipeline Progress at Alnylam - Analyst Blog", "Pipeline Update at Alnylam - Analyst Blog", "Pipeline Progress at Alnylam - Analyst Blog", "Alnylam Up on Positive Phase I Data - Analyst Blog", "Orphan Drug Status for AEGR's Juxtapid in Japan - Analyst Blog", "Data Published on Alnylam's ATTR Candidates - Analyst Blog", "Alnylam Wins Orphan Drug Status - Analyst Blog", "Pipeline Progress at Alnylam - Analyst Blog", "Narrower-than-Expected Q2 Loss at Alnylam - Analyst Blog", "Aegerion's Lojuxta Gets EU Approval - Analyst Blog", "Best Stocks: Isis, Gilead, Celgene, and Regeneron Take Over the Top Ranks", "Market Wrap for Friday, July 12: Stocks Rise as S&P 500 Closes At New All-Time High", "Northera NDA Resubmitted By Chelsea - Analyst Blog", "Market Wrap for Thursday, July 11: Market Jumps on Dovish Bernanke Comments", "Australian Approval for Vertex' Kalydeco - Analyst Blog", "Good News for Alnylam - Analyst Blog", "Positive Data on Alnylam's Candidate - Analyst Blog", "Celgene Inks Oncology Deal - Analyst Blog", "Celgene presents Revlimid Data - Analyst Blog", "Gilead Retained at Neutral - Analyst Blog", "CHMP Positive on Aegerion's Lojuxta - Analyst Blog", "Alnylam Narrows Loss, Sales Fall - Analyst Blog", "Pipeline Progresses at ViroPharma - Analyst Blog", "BioMarin Files Vimizim MA in Brazil - Analyst Blog", "Alnylam Initiates ALN-TTRsc Study - Analyst Blog", "Loss Widens at Alnylam, Sales Fall - Analyst Blog", "Alnylam-MDCO Join for ALN-PCS - Analyst Blog", "Alnylam's ALN-VSP Data Published - Analyst Blog", "Mid-Morning Market Update: Goldman Sachs Crushes on Earnings, Research in Motion Rises on Visa Approval", "Alnylam Prices Public Offering - Analyst Blog", "Best Stocks: Biotech Still Holding Top Spots", "Pipeline Update from Alnylam - Analyst Blog", "Alnylam-Tekmira Settle Up - Analyst Blog", "Isis Misses on Both Counts - Analyst Blog", "Revenues Decline at Alnylam - Analyst Blog", "Casey Analyst Forecasts Explosive Biotech Growth", "Isis Pharma Owns 18% of Regulus - Analyst Blog", "Alnylam-ISIS Venture Prices IPO - Analyst Blog", "Alnylam to Raise $125 Million - Analyst Blog", "Alnylam & Monsanto Collaborate - Analyst Blog", "Alnylam/Isis's Regulus to Go Public - Analyst Blog", "Biogen Inks Deal with Regulus - Analyst Blog", "Alnylam Pharma Revs In-Line - Analyst Blog", "Zacks #1 Rank Additions for Monday - Tale of the Tape", "Alnylam Earns Milestone Payment - Analyst Blog", "Zacks #1 Rank Additions for Thursday - Tale of the Tape", "Alnylam Presents Data on ALN-RSV01 - Analyst Blog", "Zacks #1 Rank Additions for Tuesday - Tale of the Tape", "Positive Data on Alnylam Candidate - Analyst Blog", "Zacks #1 Rank Additions for Friday - Tale of the Tape", "Company News for July 17, 2012 - Corporate Summary", "Alnylam Inks Oncology Deal - Analyst Blog", "Orphan Status for Alnylam Drug - Analyst Blog", "How the Short Ratio Can Lead to Big Gains - Screen of the Week", "Zacks #1 Rank Additions for Friday - Tale of the Tape", "The Zacks Analyst Blog Highlights: Amgen, Sanofi, Regeneron, Alnylam and Coach - Press Releases", "Encouraging Data on Amgen Candidate - Analyst Blog", "Company News for February 15, 2012 - Corporate Summary", "Alnylam Delivers In-Line Numbers - Analyst Blog", "Alnylam Gets New Patent - Analyst Blog", "Alnylam to Cut 33% Jobs - Analyst Blog", "Alnylam Down to Neutral - Analyst Blog", "Alnylam Narrows Loss - Analyst Blog", "Still Bullish on Alnylam - Analyst Blog", "Alnylam Completes Trial Enrollment - Analyst Blog", "Alnylam Reveals ALNTTR01 Trial Data - Analyst Blog", "Hearty Profits: Companies Racing to Develop the Next Big Cholesterol Drug", "Options Ideas: 24 Healthcare Stocks With Bullish Options Sentiment", "4 Small Caps That Could Pop", "Alnylam States Preclinical Data - Analyst Blog"], "Elapsed Time": ["1 DAY AGO", "5 DAYS AGO", "JUN 11, 2020", "JUN 9, 2020", "JUN 2, 2020", "JUN 1, 2020", "MAY 29, 2020", "MAY 28, 2020", "1 DAY AGO", "MAY 24, 2020", "MAY 23, 2020", "MAY 21, 2020", "MAY 6, 2020", "MAY 6, 2020", "MAY 6, 2020", "MAY 6, 2020", "MAY 26, 2020", "MAY 4, 2020", "MAY 4, 2020", "MAY 4, 2020", "MAY 4, 2020", "MAY 4, 2020", "APR 21, 2020", "APR 16, 2020", "MAY 4, 2020", "APR 14, 2020", "APR 13, 2020", "APR 13, 2020", "APR 13, 2020", "APR 13, 2020", "APR 13, 2020", "APR 13, 2020", "APR 15, 2020", "APR 12, 2020", "APR 10, 2020", "APR 7, 2020", "APR 7, 2020", "APR 6, 2020", "MAR 25, 2020", "MAR 16, 2020", "APR 13, 2020", "MAR 12, 2020", "MAR 12, 2020", "MAR 10, 2020", "MAR 10, 2020", "MAR 4, 2020", "MAR 4, 2020", "MAR 3, 2020", "MAR 15, 2020", "MAR 12, 2020", "MAR 12, 2020", "FEB 6, 2020", "FEB 6, 2020", "FEB 6, 2020", "FEB 6, 2020", "MAR 3, 2020", "JAN 31, 2020", "JAN 29, 2020", "JAN 23, 2020", "JAN 17, 2020", "JAN 13, 2020", "JAN 9, 2020", "JAN 8, 2020", "FEB 4, 2020", "JAN 3, 2020", "JAN 2, 2020", "DEC 27, 2019", "DEC 27, 2019", "DEC 23, 2019", "DEC 23, 2019", "DEC 20, 2019", "JAN 7, 2020", "DEC 5, 2019", "DEC 5, 2019", "DEC 5, 2019", "DEC 5, 2019", "DEC 5, 2019", "DEC 4, 2019", "DEC 3, 2019", "DEC 16, 2019", "NOV 29, 2019", "NOV 26, 2019", "NOV 26, 2019", "NOV 25, 2019", "NOV 25, 2019", "NOV 25, 2019", "NOV 23, 2019", "DEC 3, 2019", "NOV 21, 2019", "NOV 18, 2019", "NOV 10, 2019", "OCT 31, 2019", "OCT 31, 2019", "OCT 31, 2019", "OCT 31, 2019", "NOV 22, 2019", "OCT 14, 2019", "OCT 1, 2019", "OCT 1, 2019", "SEP 30, 2019", "SEP 10, 2019", "SEP 9, 2019", "SEP 3, 2019", "OCT 22, 2019", "AUG 26, 2019", "AUG 19, 2019", "AUG 6, 2019", "AUG 6, 2019", "JUL 31, 2019", "JUL 23, 2019", "JUL 20, 2019", "AUG 30, 2019", "JUN 17, 2019", "MAY 30, 2019", "MAY 20, 2019", "MAY 7, 2019", "MAY 6, 2019", "MAY 2, 2019", "MAY 1, 2019", "JUL 18, 2019", "APR 22, 2019", "APR 16, 2019", "APR 16, 2019", "APR 15, 2019", "APR 15, 2019", "APR 11, 2019", "APR 9, 2019", "MAY 1, 2019", "APR 22, 2019", "APR 16, 2019", "MAR 30, 2019", "MAR 18, 2019", "MAR 14, 2019", "MAR 12, 2019", "APR 8, 2019", "MAR 7, 2019", "MAR 6, 2019", "MAR 6, 2019", "MAR 6, 2019", "MAR 4, 2019", "FEB 28, 2019", "FEB 21, 2019", "MAR 9, 2019", "FEB 12, 2019", "FEB 8, 2019", "FEB 7, 2019", "FEB 7, 2019", "JAN 25, 2019", "JAN 24, 2019", "JAN 23, 2019", "FEB 14, 2019", "JAN 22, 2019", "JAN 21, 2019", "JAN 15, 2019", "JAN 15, 2019", "JAN 15, 2019", "JAN 10, 2019", "JAN 10, 2019", "JAN 23, 2019", "JAN 8, 2019", "JAN 8, 2019", "JAN 7, 2019", "DEC 28, 2018", "DEC 18, 2018", "DEC 7, 2018", "NOV 27, 2018", "JAN 9, 2019", "NOV 26, 2018", "NOV 15, 2018", "NOV 14, 2018", "NOV 12, 2018", "NOV 12, 2018", "NOV 8, 2018", "NOV 8, 2018", "NOV 26, 2018", "NOV 7, 2018", "NOV 7, 2018", "NOV 6, 2018", "NOV 2, 2018", "NOV 1, 2018", "NOV 1, 2018", "NOV 1, 2018", "NOV 7, 2018", "OCT 30, 2018", "OCT 30, 2018", "OCT 29, 2018", "OCT 29, 2018", "OCT 26, 2018", "OCT 25, 2018", "OCT 22, 2018", "OCT 31, 2018", "OCT 5, 2018", "OCT 4, 2018", "OCT 4, 2018", "OCT 4, 2018", "OCT 4, 2018", "OCT 3, 2018", "OCT 2, 2018", "OCT 16, 2018", "SEP 14, 2018", "SEP 12, 2018", "SEP 10, 2018", "SEP 7, 2018", "SEP 6, 2018", "SEP 6, 2018", "SEP 5, 2018", "SEP 14, 2018", "SEP 3, 2018", "AUG 31, 2018", "AUG 29, 2018", "AUG 28, 2018", "AUG 28, 2018", "AUG 27, 2018", "AUG 27, 2018", "SEP 4, 2018", "AUG 27, 2018", "AUG 27, 2018", "AUG 26, 2018", "AUG 22, 2018", "AUG 22, 2018", "AUG 22, 2018", "AUG 20, 2018", "AUG 27, 2018", "AUG 17, 2018", "AUG 17, 2018", "AUG 15, 2018", "AUG 15, 2018", "AUG 13, 2018", "AUG 13, 2018", "AUG 13, 2018", "AUG 17, 2018", "AUG 8, 2018", "AUG 6, 2018", "AUG 6, 2018", "AUG 6, 2018", "AUG 3, 2018", "AUG 2, 2018", "AUG 2, 2018", "AUG 13, 2018", "AUG 1, 2018", "JUL 30, 2018", "JUL 12, 2018", "JUL 9, 2018", "JUL 2, 2018", "JUL 2, 2018", "JUN 28, 2018", "AUG 2, 2018", "JUN 8, 2018", "JUN 8, 2018", "JUN 8, 2018", "JUN 4, 2018", "JUN 4, 2018", "JUN 4, 2018", "JUN 3, 2018", "JUN 11, 2018", "JUN 8, 2018", "JUN 8, 2018", "MAY 16, 2018", "MAY 14, 2018", "MAY 9, 2018", "MAY 8, 2018", "MAY 4, 2018", "MAY 31, 2018", "APR 30, 2018", "APR 27, 2018", "APR 23, 2018", "APR 20, 2018", "APR 17, 2018", "APR 3, 2018", "APR 3, 2018", "APR 30, 2018", "APR 2, 2018", "APR 2, 2018", "APR 2, 2018", "APR 2, 2018", "APR 2, 2018", "APR 2, 2018", "MAR 30, 2018", "APR 2, 2018", "MAR 26, 2018", "MAR 24, 2018", "MAR 24, 2018", "MAR 23, 2018", "MAR 22, 2018", "MAR 22, 2018", "MAR 20, 2018", "MAR 29, 2018", "MAR 12, 2018", "MAR 12, 2018", "MAR 12, 2018", "MAR 12, 2018", "MAR 9, 2018", "MAR 6, 2018", "MAR 3, 2018", "MAR 12, 2018", "FEB 26, 2018", "FEB 22, 2018", "FEB 12, 2018", "FEB 9, 2018", "FEB 9, 2018", "FEB 6, 2018", "FEB 2, 2018", "FEB 26, 2018", "JAN 24, 2018", "JAN 22, 2018", "JAN 22, 2018", "JAN 15, 2018", "JAN 15, 2018", "JAN 14, 2018", "JAN 13, 2018", "JAN 30, 2018", "JAN 24, 2018", "JAN 22, 2018", "JAN 22, 2018", "JAN 3, 2018", "DEC 31, 2017", "DEC 28, 2017", "DEC 22, 2017", "JAN 10, 2018", "JAN 9, 2018", "DEC 20, 2017", "DEC 19, 2017", "DEC 18, 2017", "DEC 15, 2017", "DEC 15, 2017", "DEC 21, 2017", "DEC 13, 2017", "DEC 6, 2017", "DEC 5, 2017", "DEC 4, 2017", "NOV 29, 2017", "NOV 29, 2017", "NOV 28, 2017", "DEC 15, 2017", "NOV 17, 2017", "NOV 17, 2017", "NOV 16, 2017", "NOV 16, 2017", "NOV 16, 2017", "NOV 15, 2017", "NOV 14, 2017", "NOV 21, 2017", "NOV 14, 2017", "NOV 10, 2017", "NOV 8, 2017", "NOV 8, 2017", "NOV 7, 2017", "NOV 7, 2017", "NOV 6, 2017", "NOV 14, 2017", "NOV 6, 2017", "NOV 6, 2017", "NOV 6, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 2, 2017", "NOV 2, 2017", "NOV 6, 2017", "OCT 30, 2017", "OCT 30, 2017", "OCT 26, 2017", "OCT 23, 2017", "OCT 13, 2017", "OCT 6, 2017", "OCT 5, 2017", "OCT 31, 2017", "OCT 3, 2017", "SEP 23, 2017", "SEP 21, 2017", "SEP 21, 2017", "SEP 21, 2017", "SEP 20, 2017", "SEP 20, 2017", "OCT 4, 2017", "SEP 20, 2017", "SEP 20, 2017", "SEP 20, 2017", "SEP 20, 2017", "SEP 20, 2017", "SEP 20, 2017", "SEP 20, 2017", "SEP 20, 2017", "SEP 20, 2017", "SEP 20, 2017", "SEP 20, 2017", "SEP 18, 2017", "SEP 15, 2017", "SEP 8, 2017", "SEP 7, 2017", "SEP 20, 2017", "SEP 7, 2017", "SEP 7, 2017", "SEP 7, 2017", "SEP 7, 2017", "SEP 6, 2017", "SEP 5, 2017", "SEP 4, 2017", "SEP 7, 2017", "AUG 29, 2017", "AUG 28, 2017", "AUG 27, 2017", "AUG 21, 2017", "AUG 14, 2017", "AUG 14, 2017", "AUG 11, 2017", "SEP 1, 2017", "AUG 10, 2017", "AUG 9, 2017", "AUG 8, 2017", "AUG 8, 2017", "AUG 8, 2017", "AUG 8, 2017", "AUG 8, 2017", "AUG 10, 2017", "JUL 12, 2017", "JUL 11, 2017", "JUL 10, 2017", "JUL 10, 2017", "JUL 7, 2017", "JUN 29, 2017", "JUN 29, 2017", "JUL 21, 2017", "JUN 25, 2017", "JUN 15, 2017", "JUN 11, 2017", "JUN 8, 2017", "JUN 1, 2017", "JUN 1, 2017", "MAY 26, 2017", "JUN 28, 2017", "MAY 25, 2017", "MAY 24, 2017", "MAY 17, 2017", "MAY 16, 2017", "MAY 15, 2017", "MAY 15, 2017", "MAY 15, 2017", "MAY 25, 2017", "MAY 25, 2017", "MAY 5, 2017", "MAY 5, 2017", "MAY 4, 2017", "APR 27, 2017", "APR 26, 2017", "APR 12, 2017", "MAY 10, 2017", "APR 2, 2017", "MAR 30, 2017", "MAR 23, 2017", "MAR 23, 2017", "MAR 20, 2017", "FEB 28, 2017", "FEB 27, 2017", "APR 7, 2017", "FEB 21, 2017", "FEB 20, 2017", "FEB 9, 2017", "FEB 9, 2017", "FEB 9, 2017", "FEB 6, 2017", "FEB 3, 2017", "FEB 23, 2017", "JAN 11, 2017", "JAN 11, 2017", "JAN 11, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 7, 2017", "JAN 6, 2017", "JAN 24, 2017", "DEC 31, 2016", "DEC 29, 2016", "DEC 17, 2016", "DEC 7, 2016", "DEC 1, 2016", "NOV 22, 2016", "NOV 17, 2016", "JAN 6, 2017", "NOV 9, 2016", "NOV 7, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 3, 2016", "NOV 3, 2016", "OCT 19, 2016", "NOV 15, 2016", "OCT 17, 2016", "OCT 12, 2016", "OCT 12, 2016", "OCT 10, 2016", "OCT 10, 2016", "OCT 7, 2016", "OCT 7, 2016", "OCT 17, 2016", "OCT 6, 2016", "OCT 6, 2016", "OCT 6, 2016", "OCT 6, 2016", "OCT 6, 2016", "OCT 6, 2016", "OCT 6, 2016", "OCT 6, 2016", "SEP 29, 2016", "SEP 29, 2016", "SEP 24, 2016", "SEP 19, 2016", "SEP 8, 2016", "SEP 2, 2016", "AUG 22, 2016", "OCT 6, 2016", "AUG 10, 2016", "AUG 4, 2016", "AUG 4, 2016", "AUG 4, 2016", "AUG 3, 2016", "AUG 2, 2016", "JUL 25, 2016", "AUG 12, 2016", "JUL 8, 2016", "JUL 7, 2016", "JUL 5, 2016", "JUL 5, 2016", "JUL 5, 2016", "JUL 1, 2016", "JUN 25, 2016", "JUL 8, 2016", "MAY 31, 2016", "MAY 27, 2016", "MAY 26, 2016", "MAY 26, 2016", "MAY 24, 2016", "MAY 23, 2016", "MAY 4, 2016", "JUN 13, 2016", "MAY 4, 2016", "MAY 3, 2016", "MAY 2, 2016", "MAY 2, 2016", "APR 12, 2016", "APR 7, 2016", "APR 6, 2016", "MAY 4, 2016", "MAR 28, 2016", "MAR 18, 2016", "MAR 14, 2016", "MAR 10, 2016", "MAR 7, 2016", "FEB 23, 2016", "FEB 16, 2016", "MAR 31, 2016", "MAR 28, 2016", "MAR 18, 2016", "MAR 14, 2016", "JAN 19, 2016", "JAN 13, 2016", "JAN 9, 2016", "FEB 16, 2016", "DEC 18, 2015", "DEC 17, 2015", "DEC 14, 2015", "DEC 7, 2015", "DEC 7, 2015", "DEC 1, 2015", "DEC 1, 2015", "DEC 22, 2015", "NOV 17, 2015", "NOV 15, 2015", "NOV 14, 2015", "NOV 12, 2015", "NOV 10, 2015", "NOV 9, 2015", "NOV 6, 2015", "NOV 20, 2015", "NOV 6, 2015", "NOV 6, 2015", "NOV 6, 2015", "NOV 6, 2015", "NOV 6, 2015", "NOV 5, 2015", "NOV 5, 2015", "NOV 6, 2015", "NOV 4, 2015", "NOV 4, 2015", "NOV 3, 2015", "NOV 3, 2015", "NOV 2, 2015", "NOV 2, 2015", "NOV 2, 2015", "NOV 4, 2015", "NOV 2, 2015", "NOV 2, 2015", "OCT 23, 2015", "OCT 15, 2015", "OCT 13, 2015", "OCT 9, 2015", "OCT 2, 2015", "NOV 2, 2015", "SEP 24, 2015", "SEP 16, 2015", "SEP 9, 2015", "SEP 4, 2015", "SEP 3, 2015", "SEP 2, 2015", "SEP 1, 2015", "SEP 29, 2015", "AUG 31, 2015", "AUG 31, 2015", "AUG 31, 2015", "AUG 7, 2015", "AUG 7, 2015", "AUG 7, 2015", "AUG 6, 2015", "AUG 31, 2015", "AUG 31, 2015", "AUG 31, 2015", "JUN 24, 2015", "JUN 18, 2015", "JUN 15, 2015", "JUN 11, 2015", "JUL 27, 2015", "JUN 11, 2015", "JUN 2, 2015", "MAY 27, 2015", "MAY 22, 2015", "MAY 18, 2015", "MAY 8, 2015", "MAY 8, 2015", "JUN 11, 2015", "APR 28, 2015", "APR 23, 2015", "APR 23, 2015", "APR 22, 2015", "APR 22, 2015", "APR 22, 2015", "APR 21, 2015", "APR 29, 2015", "APR 9, 2015", "APR 1, 2015", "MAR 30, 2015", "MAR 25, 2015", "MAR 25, 2015", "MAR 23, 2015", "MAR 16, 2015", "APR 14, 2015", "MAR 9, 2015", "MAR 3, 2015", "MAR 2, 2015", "MAR 2, 2015", "MAR 2, 2015", "FEB 28, 2015", "FEB 27, 2015", "MAR 13, 2015", "FEB 19, 2015", "FEB 19, 2015", "FEB 17, 2015", "FEB 17, 2015", "FEB 17, 2015", "FEB 16, 2015", "FEB 14, 2015", "FEB 23, 2015", "FEB 13, 2015", "FEB 13, 2015", "FEB 12, 2015", "FEB 12, 2015", "FEB 12, 2015", "FEB 11, 2015", "FEB 11, 2015", "FEB 13, 2015", "FEB 10, 2015", "FEB 10, 2015", "FEB 9, 2015", "FEB 9, 2015", "FEB 9, 2015", "FEB 9, 2015", "FEB 9, 2015", "FEB 11, 2015", "FEB 6, 2015", "FEB 6, 2015", "FEB 5, 2015", "FEB 4, 2015", "FEB 3, 2015", "FEB 3, 2015", "FEB 2, 2015", "FEB 6, 2015", "JAN 30, 2015", "JAN 29, 2015", "JAN 28, 2015", "JAN 27, 2015", "JAN 23, 2015", "JAN 21, 2015", "JAN 21, 2015", "JAN 30, 2015", "JAN 21, 2015", "JAN 21, 2015", "JAN 21, 2015", "JAN 20, 2015", "JAN 19, 2015", "JAN 11, 2015", "JAN 10, 2015", "JAN 21, 2015", "JAN 3, 2015", "JAN 2, 2015", "DEC 24, 2014", "DEC 15, 2014", "DEC 9, 2014", "DEC 9, 2014", "DEC 8, 2014", "JAN 9, 2015", "DEC 4, 2014", "NOV 19, 2014", "NOV 17, 2014", "NOV 12, 2014", "NOV 7, 2014", "NOV 6, 2014", "NOV 6, 2014", "DEC 8, 2014", "NOV 4, 2014", "NOV 4, 2014", "NOV 3, 2014", "NOV 3, 2014", "OCT 31, 2014", "OCT 27, 2014", "OCT 21, 2014", "NOV 5, 2014", "OCT 15, 2014", "OCT 14, 2014", "OCT 14, 2014", "OCT 13, 2014", "OCT 13, 2014", "OCT 13, 2014", "OCT 13, 2014", "OCT 16, 2014", "SEP 26, 2014", "SEP 18, 2014", "SEP 15, 2014", "SEP 5, 2014", "AUG 13, 2014", "AUG 11, 2014", "AUG 7, 2014", "OCT 6, 2014", "JUN 26, 2014", "MAY 12, 2014", "APR 30, 2014", "APR 10, 2014", "APR 10, 2014", "APR 8, 2014", "MAR 12, 2014", "AUG 7, 2014", "FEB 25, 2014", "FEB 24, 2014", "FEB 14, 2014", "FEB 14, 2014", "FEB 13, 2014", "FEB 7, 2014", "FEB 5, 2014", "MAR 3, 2014", "JAN 24, 2014", "JAN 22, 2014", "JAN 22, 2014", "JAN 16, 2014", "JAN 15, 2014", "JAN 14, 2014", "JAN 14, 2014", "JAN 29, 2014", "JAN 13, 2014", "JAN 13, 2014", "JAN 13, 2014", "JAN 13, 2014", "JAN 13, 2014", "JAN 9, 2014", "DEC 23, 2013", "JAN 14, 2014", "NOV 20, 2013", "NOV 18, 2013", "NOV 18, 2013", "NOV 18, 2013", "NOV 7, 2013", "NOV 7, 2013", "NOV 7, 2013", "NOV 26, 2013", "OCT 14, 2013", "OCT 8, 2013", "OCT 3, 2013", "SEP 24, 2013", "SEP 10, 2013", "AUG 29, 2013", "AUG 21, 2013", "OCT 30, 2013", "AUG 14, 2013", "AUG 5, 2013", "JUL 29, 2013", "JUL 12, 2013", "JUL 11, 2013", "JUL 11, 2013", "JUL 10, 2013", "AUG 19, 2013", "JUL 1, 2013", "JUN 27, 2013", "JUN 26, 2013", "JUN 25, 2013", "JUN 3, 2013", "MAY 7, 2013", "APR 23, 2013", "JUL 5, 2013", "MAR 19, 2013", "FEB 8, 2013", "FEB 5, 2013", "JAN 31, 2013", "JAN 16, 2013", "JAN 16, 2013", "APR 22, 2013", "JAN 8, 2013", "NOV 19, 2012", "NOV 7, 2012", "NOV 7, 2012", "OCT 17, 2012", "OCT 12, 2012", "OCT 5, 2012", "JAN 15, 2013", "AUG 29, 2012", "AUG 22, 2012", "AUG 16, 2012", "AUG 7, 2012", "AUG 6, 2012", "AUG 6, 2012", "AUG 2, 2012", "SEP 6, 2012", "JUL 24, 2012", "JUL 23, 2012", "JUL 20, 2012", "JUL 17, 2012", "JUL 13, 2012", "JUN 21, 2012", "JUN 12, 2012", "JUL 27, 2012", "MAR 28, 2012", "MAR 27, 2012", "FEB 15, 2012", "FEB 13, 2012", "FEB 1, 2012", "JAN 23, 2012", "JAN 20, 2012", "MAY 4, 2012", "DEC 7, 2011", "DEC 1, 2011", "NOV 25, 2011", "AUG 30, 2011", "JUN 7, 2011", "DEC 10, 2010", "DEC 30, 2011"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/why-dynavax-novavax-and-vir-biotechnology-stocks-jumped-today-2020-06-24", "https://www.nasdaq.com/articles/is-alnylam-a-good-biotech-stock-to-buy-now-2020-06-21", "https://www.nasdaq.com/articles/alnylam-to-present-at-the-goldman-sachs-global-healthcare-conference-webcast-at-8%3A00-am-et", "https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-fate-nwl-alny-2020-06-09", "https://www.nasdaq.com/articles/alnylam-to-present-at-jefferies-virtual-healthcare-conference-webcast-at-10%3A30-am-et-2020", "https://www.nasdaq.com/articles/vir-biotechnology-is-bucking-the-biotech-covid-19-trends-and-stands-to-win-2020-06-01", "https://www.nasdaq.com/articles/got-%243000-here-are-3-great-biotech-stocks-to-buy-right-now-2020-05-29", "https://www.nasdaq.com/articles/analysts-expect-fxh-to-hit-%2498-2020-05-28", "https://www.nasdaq.com/articles/why-dynavax-novavax-and-vir-biotechnology-stocks-jumped-today-2020-06-24", "https://www.nasdaq.com/articles/is-arrowhead-pharmaceuticals-a-buy-2020-05-24", "https://www.nasdaq.com/articles/better-coronavirus-stock%3A-gilead-sciences-or-vir-biotechnology-2020-05-23", "https://www.nasdaq.com/articles/is-alnylam-pharmaceuticals-a-buy-2020-05-21", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-alny-q1-2020-earnings-call-transcript-2020-05-06", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-lowers-2020-sales-expectations-due-to-covid-19-2020-05-06", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc.-q1-adjusted-earnings-beat-estimates-2020-05-06", "https://www.nasdaq.com/articles/alnylam-q1-20-earnings-conference-call-at-8%3A30-am-et-2020-05-06", "https://www.nasdaq.com/articles/argx-soars-on-adapt-trial-data-mrks-deals-collaborations-to-fight-covid-19-alny-on-watch", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-airlines-banks-insurers-pge-2020-05-04", "https://www.nasdaq.com/articles/vir-biotechnology-and-alnylam-pick-a-coronavirus-vaccine-candidate-to-pursue-2020-05-04", "https://www.nasdaq.com/articles/vir-alnylam-identify-covid-19-therapy-candidate-plan-human-trials-by-year-end-2020-05-04", "https://www.nasdaq.com/articles/vir-biotechnology-alnylam-identify-vir-2703-candidate-for-treatment-of-covid-19-2020-05-04", "https://www.nasdaq.com/articles/vir-alnylam-pick-coronavirus-therapy-candidate-plan-human-trials-by-year-end-2020-05-04", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-reaches-analyst-target-price-2020-04-21", "https://www.nasdaq.com/articles/is-vir-biotechnology-stock-a-buy-2020-04-16", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-airlines-banks-insurers-oil-stocks-2020-05-04", "https://www.nasdaq.com/articles/stock-to-watch%3A-alnylam-pharma-alny-2020-04-14", "https://www.nasdaq.com/articles/financial-sector-update-for-04-13-2020%3A-lamrbxalnykkrmfa-2020-04-13", "https://www.nasdaq.com/articles/alnylam-scores-a-%242-billion-investment-from-blackstone-2020-04-13", "https://www.nasdaq.com/articles/financial-sector-update-for-04-13-2020%3A-bxalnykkrmfa-2020-04-13", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-amazon.com-netflix-royal-caribbean-cruises-sabre-corp", "https://www.nasdaq.com/articles/blackstone-to-invest-up-to-%242-bln-in-alnylam-2020-04-13", "https://www.nasdaq.com/articles/blackstone-invests-%242-bln-in-alnylam-boosting-gene-silencing-drug-development-2020-04-13", "https://www.nasdaq.com/articles/2-top-small-cap-stocks-to-buy-right-now-2020-04-15", "https://www.nasdaq.com/articles/better-buy%3A-alnylam-pharmaceuticals-vs.-vir-biotechnology-2020-04-12", "https://www.nasdaq.com/articles/analysts-see-17-upside-for-vug-2020-04-10", "https://www.nasdaq.com/articles/here-are-all-the-companies-working-on-covid-19-vaccines-treatments-and-testing-2020-04-07", "https://www.nasdaq.com/articles/immu-soars-mlnd-leaves-investors-starved-vir-gsk-to-develop-covid-19-drugs-2020-04-07", "https://www.nasdaq.com/articles/alnylam-dicerna-form-rnai-therapeutics-collaboration-for-alpha-1-liver-disease-2020-04-06", "https://www.nasdaq.com/articles/fxh-dxcm-alny-sgen%3A-large-inflows-detected-at-etf-2020-03-25", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-wlk-alny-lulu-2020-03-16", "https://www.nasdaq.com/articles/blackstone-invests-%242-bln-in-alnylam-pharma-2020-04-13", "https://www.nasdaq.com/articles/why-alnylam-pharmaceuticals-intuitive-surgical-and-resmed-stocks-sank-today-2020-03-12", "https://www.nasdaq.com/articles/relative-strength-alert-for-alnylam-pharmaceuticals-2020-03-12", "https://www.nasdaq.com/articles/alnylam-pharma-to-present-at-barclays-global-conference-webcast-at-2%3A35-pm-et-2020-03-10", "https://www.nasdaq.com/articles/analysts-see-24-gains-ahead-for-fxh-2020-03-10", "https://www.nasdaq.com/articles/who-says-coronavirus-death-rate-is-higher-than-previously-thought-2020-03-04", "https://www.nasdaq.com/articles/vir-biotechnology-and-alnylam-join-the-fight-against-covid-19-2020-03-04", "https://www.nasdaq.com/articles/alnylam-to-cowen-company-healthcare-conference-webcast-at-10%3A40-am-et-2020-03-03", "https://www.nasdaq.com/articles/better-coronavirus-stock%3A-inovio-pharmaceuticals-vs.-vir-biotechnology-2020-03-15", "https://www.nasdaq.com/articles/why-alnylam-pharmaceuticals-intuitive-surgical-and-resmed-stocks-sank-today-2020-03-12", "https://www.nasdaq.com/articles/relative-strength-alert-for-alnylam-pharmaceuticals-2020-03-12", "https://www.nasdaq.com/articles/alnylam-beats-revenue-estimates-but-misses-on-earnings-2020-02-06", "https://www.nasdaq.com/articles/alnylam-pharma-posts-wider-loss-in-q4-quick-facts-2020-02-06", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc.-q4-adjusted-earnings-beat-estimates-2020-02-06", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-q4-19-earnings-conference-call-at-8%3A30-am-et-2020-02-06", "https://www.nasdaq.com/articles/alnylam-pharma-says-givlaari-approved-in-eu-for-acute-hepatic-porphyria-2020-03-03", "https://www.nasdaq.com/articles/alnylam-pharma-reports-positive-chmp-opinion-for-givosiran-quick-facts-2020-01-31", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-lly-alny-mrvl-2020-01-29", "https://www.nasdaq.com/articles/first-week-of-alny-september-18th-options-trading-2020-01-23", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-alny-ehth-pbyi-2020-01-17", "https://www.nasdaq.com/articles/alnylam-pharma-to-present-at-j.p.-morgan-conference-webcast-at-1%3A30-pm-et-2020-01-13", "https://www.nasdaq.com/articles/why-alnylam-pharmaceuticals-rose-57.9-in-2019-2020-01-09", "https://www.nasdaq.com/articles/spdr-sp-biotech-etf-experiences-big-outflow-2020-01-08", "https://www.nasdaq.com/articles/peek-under-the-hood%3A-iwd-has-10-upside-2020-02-04", "https://www.nasdaq.com/articles/these-2-stocks-will-fall-after-the-new-year-2020-01-03", "https://www.nasdaq.com/articles/analysts-expect-bbh-to-hit-%24157-2020-01-02", "https://www.nasdaq.com/articles/xbi-icpt-sgen-alny%3A-large-inflows-detected-at-etf-2019-12-27", "https://www.nasdaq.com/articles/3-rare-disease-drug-launches-to-watch-in-2020-2019-12-27", "https://www.nasdaq.com/articles/these-were-the-10-best-healthcare-stocks-of-2019-2019-12-23", "https://www.nasdaq.com/articles/ussg-idna%3A-big-etf-inflows-2019-12-23", "https://www.nasdaq.com/articles/heres-why-dicerna-pharmaceuticals-is-falling-today-2019-12-20", "https://www.nasdaq.com/articles/these-3-healthcare-stocks-are-set-to-soar-in-2020-says-cowen-2020-01-07", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-etsy-bpmc-alny-2019-12-05", "https://www.nasdaq.com/articles/alnylam-pharma-to-present-at-piper-jaffray-conference-webcast-at-9%3A00-am-et-2019-12-05", "https://www.nasdaq.com/articles/why-has-alnylams-stock-gained-25-in-the-last-two-weeks-2019-12-05-0", "https://www.nasdaq.com/articles/why-has-alnylams-stock-gained-25-in-the-last-two-weeks-2019-12-05-1", "https://www.nasdaq.com/articles/why-has-alnylams-stock-gained-25-in-the-last-two-weeks-2019-12-05", "https://www.nasdaq.com/articles/heres-why-arrowhead-pharmaceuticals-is-tumbling-today-2019-12-04", "https://www.nasdaq.com/articles/heres-why-alnylam-pharmaceuticals-rose-35.1-in-november-2019-12-03", "https://www.nasdaq.com/articles/reasons-behind-the-40-jump-in-castle-biosciences-stock-since-early-november-2019-12-16", "https://www.nasdaq.com/articles/5-new-drug-approvals-the-fda-gave-top-priority-2019-11-29", "https://www.nasdaq.com/articles/commit-to-purchase-alnylam-pharmaceuticals-at-%2490-earn-9.3-using-options-2019-11-26", "https://www.nasdaq.com/articles/better-buy%3A-editas-medicine-or-sangamo-therapeutics-2019-11-26", "https://www.nasdaq.com/articles/a-45-premium%3A-heres-why-the-medicines-company-is-worth-more-to-novartis-than-it-was-to-you", "https://www.nasdaq.com/articles/why-the-medicines-company-stock-is-soaring-today-2019-11-25", "https://www.nasdaq.com/articles/is-alnylam-stock-a-good-buy-now-2019-11-25", "https://www.nasdaq.com/articles/second-rnai-drug-approved%3A-biotech-investors-should-pay-attention-to-this-new-drug-class", "https://www.nasdaq.com/articles/does-a-surprise-approval-make-alnylam-pharmaceuticals-a-buy-2019-12-03", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-to-buy-in-november-2019-11-21", "https://www.nasdaq.com/articles/heres-why-the-medicines-company-moved-higher-today-2019-11-18", "https://www.nasdaq.com/articles/lpcn-awaits-fda-word-nktr-on-track-alls-well-with-five-primes-fpt155-2019-11-10", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-alny-q3-2019-earnings-call-transcript-2019-11-01", "https://www.nasdaq.com/articles/these-biotechs-were-focused-on-one-line-on-pfizers-earnings-report-2019-10-31", "https://www.nasdaq.com/articles/alnylam-pharma-q3-loss-narrows-on-strong-revenue-growth-2019-10-31", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-q3-19-earnings-conference-call-at-8%3A30-am-et-2019-10-31", "https://www.nasdaq.com/articles/alnylam-expects-to-exceed-2020-goals-with-four-marketed-products-2019-11-22", "https://www.nasdaq.com/articles/why-did-the-market-whack-this-ipo-2019-10-14", "https://www.nasdaq.com/articles/the-medicines-company-surges-on-positive-drug-trial-results-2019-10-01", "https://www.nasdaq.com/articles/the-medicines-company-is-up-161-year-to-date-but-heres-a-better-way-to-play-the-drugmakers", "https://www.nasdaq.com/articles/alny-makes-notable-cross-below-critical-moving-average-2019-09-30", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-fbt-amgn-nbix-alny-2019-09-10", "https://www.nasdaq.com/articles/3-biotech-stocks-that-could-soar-this-week-2019-09-09", "https://www.nasdaq.com/articles/health-care-sector-update-for-09-03-2019%3A-alny-emma-azn-cdtx-2019-09-03", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-alny-skx-serv-2019-10-22", "https://www.nasdaq.com/articles/heres-why-the-medicines-company-shares-jumped-13.8-today-2019-08-26", "https://www.nasdaq.com/articles/analysts-predict-13-upside-for-the-holdings-of-rxl-2019-08-19", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-alny-q2-2019-earnings-call-transcript-2019-08-06", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc.-q2-adjusted-earnings-beat-estimates-2019-08-06", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-shares-cross-above-200-dma-2019-07-31", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-cxw-alny-itgr-2019-07-23", "https://www.nasdaq.com/articles/8-more-big-pharma-events-in-2019-you-dont-want-to-miss-2019-07-20", "https://www.nasdaq.com/articles/xbi-ghdx-nvta-alny%3A-etf-inflow-alert-2019-08-30", "https://www.nasdaq.com/articles/osizs-underlying-holdings-could-mean-11-gain-potential-2019-06-17", "https://www.nasdaq.com/articles/interesting-alny-put-and-call-options-july-19th-2019-05-30", "https://www.nasdaq.com/articles/credit-suisse-absolutely-right-double-down-pfizer-stock-2019-05-20", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-now-oversold-alny-2019-05-07", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-continues-onpattro-launch-more-come-2019-05-06", "https://www.nasdaq.com/articles/can-alnylam-pharmaceuticals-stock-start-climbing-again-2019-05-02", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-alny-q1-2019-earnings-call-transcript-2019-05-01", "https://www.nasdaq.com/articles/analysts-forecast-10-gains-ahead-for-vonv-2019-07-18", "https://www.nasdaq.com/articles/why-you-shouldnt-count-regeneron-stock-out-2019-04-22", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-buy-now-2019-04-16", "https://www.nasdaq.com/articles/alnylam-initiates-phase-iii-illuminate-b-study-on-lumasiran-2019-04-16-0", "https://www.nasdaq.com/articles/how-parts-add-pbe-targets-69-2019-04-15", "https://www.nasdaq.com/articles/alnylam-alny-reports-phase-iii-envision-data-on-givosiran-2019-04-15-0", "https://www.nasdaq.com/articles/4-drugbiotech-stocks-making-mark-rnai-therapeutics-2019-04-11-0", "https://www.nasdaq.com/articles/regeneron-alnylam-extend-collaboration-for-rnai-therapeutics-2019-04-09", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc.-q1-adjusted-earnings-beat-estimates-2019-05-01", "https://www.nasdaq.com/articles/why-you-shouldnt-count-regeneron-stock-out-2019-04-22", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-buy-now-2019-04-16", "https://www.nasdaq.com/articles/2-biotechs-big-dates-april-2019-03-30", "https://www.nasdaq.com/articles/alnylams-alny-impressive-pipeline-drives-share-price-2019-03-18", "https://www.nasdaq.com/articles/add-pieces-iyh-could-be-worth-217-2019-03-14", "https://www.nasdaq.com/articles/alnylam-files-application-for-hypertension-candidate-in-uk-2019-03-12", "https://www.nasdaq.com/articles/first-week-alny-may-17th-options-trading-2019-04-08", "https://www.nasdaq.com/articles/alnylam-stock-down-despite-positive-phase-iii-givosiran-data-2019-03-07", "https://www.nasdaq.com/articles/us-stocks-move-abercrombie-fitch-nio-zayo-titan-medical-2019-03-06", "https://www.nasdaq.com/articles/alnylams-gene-silencing-drug-meets-main-goal-late-stage-study-2019-03-06", "https://www.nasdaq.com/articles/side-effects-alnylams-gene-silencing-drug-raise-concerns-shares-slip-2019-03-06", "https://www.nasdaq.com/articles/can-biotech-puppy-run-big-dogs-2019-03-04", "https://www.nasdaq.com/articles/medicines-company-mdco-q4-loss-widens-inclisiran-in-focus-2019-02-28", "https://www.nasdaq.com/articles/interesting-alny-put-and-call-options-april-18th-2019-02-21", "https://www.nasdaq.com/articles/why-is-alnylam-alny-up-3.1-since-last-earnings-report-2019-03-09", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-launched-and-ready-more-2019-02-12", "https://www.nasdaq.com/articles/alnylams-alny-q4-earnings-and-revenues-beat-estimates-2019-02-08", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-alny-q4-2018-earnings-conference-call-transcript-2019-02-07", "https://www.nasdaq.com/articles/earnings-reaction-history-alnylam-pharmaceuticals-inc-444-follow-through-indicator-66", "https://www.nasdaq.com/articles/first-week-alny-september-20th-options-trading-2019-01-25", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-celgene-regeneron-pharmaceuticals-amgen-alnylam", "https://www.nasdaq.com/articles/5-best-biotech-bets-likely-to-outperform-estimates-in-q4-2019-01-23", "https://www.nasdaq.com/articles/moderna-buy-2019-02-14", "https://www.nasdaq.com/articles/alnylam-medison-partner-to-market-rnai-products-in-israel-2019-01-22", "https://www.nasdaq.com/articles/alnylam-pharma-medison-partner-commercialize-rnai-therapeutics-israel-2019-01-21", "https://www.nasdaq.com/articles/health-care-sector-update-01152019-bpth-alny-trxc-jnj-pfe-abt-mrk-amgn-2019-01-15", "https://www.nasdaq.com/articles/health-care-sector-update-01152019-irwdktovewbsxalny-2019-01-15", "https://www.nasdaq.com/articles/health-care-sector-update-01152019-myosewbsxalny-2019-01-15", "https://www.nasdaq.com/articles/we-did-math-iwb-can-go-171-2019-01-10", "https://www.nasdaq.com/articles/thursdays-etf-movers-fbt-gdxj-2019-01-10", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-amgen-vertex-get-ec-nod-for-label-expansion-of-drugs-2019-01-23", "https://www.nasdaq.com/articles/alnylam-alny-reports-preliminary-onpattro-revenues-for-q4-2019-01-08", "https://www.nasdaq.com/articles/3-things-alnylams-management-wants-you-know-2019-01-08", "https://www.nasdaq.com/articles/alnylam-pharma-present-jp-morgan-conference-webcast-130-pm-et-2019-01-07", "https://www.nasdaq.com/articles/health-care-sector-update-12282018-alnyimmuaphaaphatovtvt-2018-12-28", "https://www.nasdaq.com/articles/rnai-goes-big-time-2018-2018-12-18", "https://www.nasdaq.com/articles/why-is-alnylam-alny-up-9.2-since-last-earnings-report-2018-12-07", "https://www.nasdaq.com/articles/alnylam-vir-begin-phase-i-ii-study-on-hepatitis-b-candidate-2018-11-27", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-loxo-celg-gain-j.p.-morgan-healthcare-conference-in-focus-2019-01", "https://www.nasdaq.com/articles/health-care-sector-update-11262018-alnybhvnedge-2018-11-26", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-launches-onpattro-2018-11-15", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-now-oversold-alny-2018-11-14", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-collects-royalties-and-spends-it-all-2018-11-12", "https://www.nasdaq.com/articles/medicines-company-mdco-q3-loss-widens-inclisiran-in-focus-2018-11-12", "https://www.nasdaq.com/articles/alnylams-alny-q3-loss-narrower-than-expected-sales-miss-2018-11-08", "https://www.nasdaq.com/articles/how-parts-add-size-targets-95-2018-11-08", "https://www.nasdaq.com/articles/health-care-sector-update-11262018-rslsalnyedgebhvn-2018-11-26", "https://www.nasdaq.com/articles/earnings-reaction-history-alnylam-pharmaceuticals-inc-375-follow-through-indicator-62", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-alny-q3-2018-earnings-conference-call-transcript-2018-11-07", "https://www.nasdaq.com/articles/pre-market-earnings-report-november-7-2018-foxa-so-hum-sre-rok-gib-cnhi-alny-andx-kors", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-ge-alny-cbm-2018-11-02", "https://www.nasdaq.com/articles/tenet-healthcare-thc-q3-earnings%3A-whats-in-the-cards-2018-11-01", "https://www.nasdaq.com/articles/eli-lilly-lly-to-report-q3-earnings%3A-whats-in-the-cards-2018-11-01", "https://www.nasdaq.com/articles/regeneron-regn-to-report-q3-earnings%3A-is-a-beat-in-store-2018-11-01", "https://www.nasdaq.com/articles/heres-why-alnylam-pharmaceuticals-crashed-119-wednesday-2018-11-07", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-expected-to-beat-earnings-estimates%3A-what-to-know-ahead-of-q3", "https://www.nasdaq.com/articles/whats-in-the-cards-for-abbvie-abbv-this-earnings-season-2018-10-30", "https://www.nasdaq.com/articles/molina-healthcares-moh-q3-earnings%3A-is-a-beat-in-store-2018-10-29", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-allergan-regeneron-pharmaceuticals-amgen-alnylam", "https://www.nasdaq.com/articles/5-drug-biotech-stocks-likely-to-beat-estimates-in-q3-earnings-2018-10-26", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-zoetis-zts-this-earnings-season-2018-10-25", "https://www.nasdaq.com/articles/alexion-alxn-to-report-q3-earnings%3A-whats-in-the-cards-2018-10-22", "https://www.nasdaq.com/articles/whats-in-the-cards-for-novavax-nvax-this-earnings-season-2018-10-31", "https://www.nasdaq.com/articles/jj-inks-deal-with-arrowhead-for-promising-liver-candidate-2018-10-05", "https://www.nasdaq.com/articles/health-care-sector-update-10042018-acstacstvalnytlry-2018-10-04", "https://www.nasdaq.com/articles/health-care-sector-update-10042018-mnkpxacstacstvalnytlr-2018-10-04", "https://www.nasdaq.com/articles/alnylam-files-clinical-trial-application-for-aln-aat02-in-uk-2018-10-04", "https://www.nasdaq.com/articles/health-care-sector-update-10042018-acstalnytlry-2018-10-04", "https://www.nasdaq.com/articles/medicines-company-to-continue-inclisiran-studies-as-planned-2018-10-03", "https://www.nasdaq.com/articles/heres-why-alynlam-pharmaceuticals-is-hogging-the-limelight-2018-10-02", "https://www.nasdaq.com/articles/alnylam-to-pursue-full-approval-rolling-nda-for-givosiran-2018-10-16", "https://www.nasdaq.com/articles/health-care-sector-update-09142018-argxcsbralny-2018-09-14", "https://www.nasdaq.com/articles/wednesdays-etf-unusual-volume-xt-2018-09-12", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-alny-acor-eros-2018-09-10", "https://www.nasdaq.com/articles/heres-why-dicerna-pharmaceuticals-inc-roller-coaster-down-18-yesterday-17-today-2018-09-07", "https://www.nasdaq.com/articles/7-lucrative-biotech-stocks-300-upside-2018-09-06", "https://www.nasdaq.com/articles/thursdays-etf-unusual-volume-iyh-2018-09-06", "https://www.nasdaq.com/articles/bbhs-holdings-imply-12-gain-potential-2018-09-05", "https://www.nasdaq.com/articles/health-care-sector-update-09142018-kalv-argxcsbralny-2018-09-14", "https://www.nasdaq.com/articles/sanofis-blood-disorder-drug-cablivi-gets-approval-in-europe-2018-09-03", "https://www.nasdaq.com/articles/alnylam-gets-european-nod-for-first-ever-rnai-therapeutic-2018-08-31", "https://www.nasdaq.com/articles/can-akcea-therapeutics-inc-and-ionis-pharmaceuticals-inc-recover-2018-08-29", "https://www.nasdaq.com/articles/pfizers-tafamidis-fails-to-impress-in-cardiomyopathy-study-2018-08-28", "https://www.nasdaq.com/articles/6-things-alnylam-investors-need-know-about-pfizers-next-blockbuster-drug-2018-08-28", "https://www.nasdaq.com/articles/mondays-etf-movers-fbt-xlu-2018-08-27", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-shares-cross-above-200-dma-2018-08-27", "https://www.nasdaq.com/articles/alnylams-shares-up-as-onpattro-gets-fda-and-eu-approvals-2018-09-04", "https://www.nasdaq.com/articles/notable-monday-option-activity-amcx-alny-ttph-2018-08-27", "https://www.nasdaq.com/articles/heres-why-alnylam-pharmaceuticals-and-ionis-pharmaceuticals-jumped-today-2018-08-27", "https://www.nasdaq.com/articles/2-blockbuster-new-drug-launches-making-investors-nervous-right-now-2018-08-26", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-label-expansion-of-regenerons-eylea-vertexs-kalydeco-2018-08-22", "https://www.nasdaq.com/articles/alnylam-completes-enrollment-in-phase-iii-givosiran-study-2018-08-22", "https://www.nasdaq.com/articles/should-alnylams-and-ionis-investors-be-worried-about-recent-ipo-2018-08-22", "https://www.nasdaq.com/articles/3-things-alnylams-management-wants-investors-know-about-launch-onpattro-2018-08-20", "https://www.nasdaq.com/articles/what-happened-stock-market-today-2018-08-27", "https://www.nasdaq.com/articles/heres-why-alnylams-shares-are-tumbling-2018-08-17", "https://www.nasdaq.com/articles/2-reasons-alnylam-stock-fell-landmark-drug-approval-2018-08-17", "https://www.nasdaq.com/articles/3-hurdles-ahead-alnylam-and-its-revolutionary-new-drug-2018-08-15", "https://www.nasdaq.com/articles/akcea-therapeutics-soars-it-readies-its-first-drug-launch-2018-08-15", "https://www.nasdaq.com/articles/commit-buy-alnylam-pharmaceuticals-60-earn-103-using-options-2018-08-13", "https://www.nasdaq.com/articles/alnylam-alny-gets-fda-nod-for-first-ever-rnai-therapeutic-2018-08-13", "https://www.nasdaq.com/articles/what-happened-stock-market-today-2018-08-13", "https://www.nasdaq.com/articles/3-tough-luck-tumbles-healthcare-are-they-buys-2018-08-17", "https://www.nasdaq.com/articles/7-biotech-stocks-big-upcoming-catalysts-2018-08-08", "https://www.nasdaq.com/articles/alnylams-alny-q2-loss-wider-than-expected-sales-beat-2018-08-06", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-q2-2018-earnings-conference-call-transcript-2018-08-06", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-launch-ready-2018-08-06", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-alny-urbn-aobc-2018-08-03", "https://www.nasdaq.com/articles/medicines-company-mdco-q2-loss-narrows-revenues-tank-y-y-2018-08-02", "https://www.nasdaq.com/articles/we-did-math-splg-can-go-36-2018-08-02", "https://www.nasdaq.com/articles/notable-monday-option-activity-alny-unh-jkhy-2018-08-13", "https://www.nasdaq.com/articles/drug-stock-q2-earnings-releases-on-aug-2%3A-zts-regn-more-2018-08-01", "https://www.nasdaq.com/articles/why-arrowhead-pharmaceuticals-inc-stock-slumped-today-2018-07-30", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-inc-buy-2018-07-12", "https://www.nasdaq.com/articles/regulus-stock-plunges-on-cash-concerns-despite-restructuring-2018-07-09", "https://www.nasdaq.com/articles/surprising-analyst-12-month-target-eqal-2018-07-02", "https://www.nasdaq.com/articles/sanofis-blood-clotting-drug-gets-positive-chmp-opinion-2018-07-02", "https://www.nasdaq.com/articles/medicines-companys-inclisiran-studies-to-continue-unmodified-2018-06-28", "https://www.nasdaq.com/articles/earnings-reaction-history-alnylam-pharmaceuticals-inc-429-follow-through-indicator-71", "https://www.nasdaq.com/articles/health-care-sector-update-06082018-alny-nvs-myov-btx-trov-2018-06-08", "https://www.nasdaq.com/articles/health-care-sector-update-06082018-admatrovalnynvs-2018-06-08", "https://www.nasdaq.com/articles/health-care-sector-update-06082018-trov-alny-nvs-2018-06-08", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-june-2018-06-04", "https://www.nasdaq.com/articles/3-strong-buy-stocks-trading-at-steep-discounts-2018-06-04", "https://www.nasdaq.com/articles/why-is-alnylam-alny-up-12.6-since-its-last-earnings-report-2018-06-04", "https://www.nasdaq.com/articles/better-buy-bellicum-pharmaceuticals-inc-vs-alnylam-pharmaceuticals-inc-2018-06-03", "https://www.nasdaq.com/articles/alnylam-reports-positive-data-on-lumasiran-in-renal-disease-2018-06-11", "https://www.nasdaq.com/articles/health-care-sector-update-06082018-alny-nvs-myov-btx-trov-2018-06-08", "https://www.nasdaq.com/articles/health-care-sector-update-06082018-admatrovalnynvs-2018-06-08", "https://www.nasdaq.com/articles/biomarin-begins-mid-stage-study-on-gene-therapy-candidate-2018-05-16", "https://www.nasdaq.com/articles/first-week-alny-may-18th-options-trading-2018-05-14", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-prepares-launch-2018-05-09", "https://www.nasdaq.com/articles/alnylam-looks-forward-2018-05-08", "https://www.nasdaq.com/articles/alnylams-alny-q1-loss-wider-than-expected-sales-miss-2018-05-04", "https://www.nasdaq.com/articles/bbhs-holdings-could-mean-24-gain-potential-2018-05-31", "https://www.nasdaq.com/articles/analysts-predict-13-gains-ahead-holdings-iwb-2018-04-30", "https://www.nasdaq.com/articles/medicines-companys-mdco-q1-loss-widens-revenues-tank-y-y-2018-04-27", "https://www.nasdaq.com/articles/health-care-sector-update-04232018-drnaalnyhsicbhvnakrxfms-2018-04-23", "https://www.nasdaq.com/articles/why-dicerna-rocketed-higher-today-2018-04-20", "https://www.nasdaq.com/articles/alnylam-alny-reports-positive-data-for-rnai-candidate-2018-04-17", "https://www.nasdaq.com/articles/ema-accepts-regeneron-sanofis-application-for-dupixent-2018-04-03", "https://www.nasdaq.com/articles/how-worried-should-alnylam-and-ionis-really-be-about-pfizers-new-data-2018-04-03", "https://www.nasdaq.com/articles/rsi-alert-alnylam-pharmaceuticals-alny-now-oversold-2018-04-30", "https://www.nasdaq.com/articles/oversold-conditions-alnylam-pharmaceuticals-alny-2018-04-02", "https://www.nasdaq.com/articles/mondays-etf-movers-gdxj-fbt-2018-04-02", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-shares-cross-below-200-dma-2018-04-02", "https://www.nasdaq.com/articles/why-pfizers-big-win-bad-news-alnylam-and-ionis-2018-04-02", "https://www.nasdaq.com/articles/pfizers-rare-disease-candidate-meets-endpoint-in-phase-iii-2018-04-02", "https://www.nasdaq.com/articles/alnylam-falls-on-pfizers-rare-disease-drug-success-2018-04-02", "https://www.nasdaq.com/articles/add-parts-acwi-could-be-worth-82-2018-03-30", "https://www.nasdaq.com/articles/why-alnylam-pharmaceuticals-inc-tanking-today-2018-04-02", "https://www.nasdaq.com/articles/3-blockbuster-drug-launches-watch-2018-2018-03-26", "https://www.nasdaq.com/articles/gilead-sciences-investors-better-watch-regeneron-alnylam-deal-2018-03-24", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-inc-buy-2018-03-24", "https://www.nasdaq.com/articles/spdr-sp-biotech-etf-experiences-big-inflow-2018-03-23", "https://www.nasdaq.com/articles/regeneron-collaborates-with-alnylam-to-develop-nash-treatment-2018-03-22", "https://www.nasdaq.com/articles/better-buy-bellicum-pharmaceuticals-inc-vs-alnylam-2018-03-22", "https://www.nasdaq.com/articles/alny-crosses-above-average-analyst-target-2018-03-20", "https://www.nasdaq.com/articles/notable-thursday-option-activity-wynn-ba-alny-2018-03-29", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-up-1.6-since-earnings-report%3A-can-it-continue-2018-03-12", "https://www.nasdaq.com/articles/why-tesla-oclaro-and-alnylam-pharmaceuticals-jumped-today-2018-03-12", "https://www.nasdaq.com/articles/health-care-sector-update-03122018-srptbiibpfesvraalnysny-2018-03-12", "https://www.nasdaq.com/articles/health-care-sector-update-03122018-svraalnysny-2018-03-12", "https://www.nasdaq.com/articles/notable-friday-option-activity-ms-etfc-alny-2018-03-09", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-march-6th-2018-03-06", "https://www.nasdaq.com/articles/why-investors-are-paying-premium-these-3-biotech-stocks-2018-03-03", "https://www.nasdaq.com/articles/health-care-sector-update-03122018-svra-srpt-alny-regn-sny-biib-pfe-2018-03-12", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-buy-2018-02-26", "https://www.nasdaq.com/articles/medicines-company-mdco-reports-q4-loss-revenues-slump-y-y-2018-02-22", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-starts-wait-approval-2018-02-12", "https://www.nasdaq.com/articles/alnylams-alny-q4-earnings-and-revenues-top-estimates-2018-02-09", "https://www.nasdaq.com/articles/math-shows-vot-can-go-142-2018-02-09", "https://www.nasdaq.com/articles/3-top-cholesterol-drug-stocks-consider-buying-now-2018-02-06", "https://www.nasdaq.com/articles/alnylams-alny-rnai-candidates-nda-gets-priority-review-2018-02-02", "https://www.nasdaq.com/articles/commit-buy-alnylam-pharmaceuticals-90-earn-122-using-options-2018-02-26", "https://www.nasdaq.com/articles/why-medicinces-company-having-outstanding-week-2018-01-24", "https://www.nasdaq.com/articles/why-2017-was-year-remember-ionis-pharmaceuticals-inc-2018-01-22", "https://www.nasdaq.com/articles/sanofi-to-acquire-haemophilia-focused-bioverativ-stock-dips-2018-01-22", "https://www.nasdaq.com/articles/prothena-prta-tumbles-18-in-a-year%3A-what-lies-ahead-2018-01-15", "https://www.nasdaq.com/articles/three-interviews-jp-morgan-healthcare-conference-2018-01-15", "https://www.nasdaq.com/articles/will-2018-be-alnylam-pharmaceuticals-incs-best-year-yet-2018-01-14", "https://www.nasdaq.com/articles/will-2018-be-ionis-pharmaceuticals-incs-best-year-yet-2018-01-13", "https://www.nasdaq.com/articles/sanofi-on-a-buyout-spree-this-month-to-buy-ablynx-for-%244.8b-2018-01-30", "https://www.nasdaq.com/articles/why-medicinces-company-having-outstanding-week-2018-01-24", "https://www.nasdaq.com/articles/why-2017-was-year-remember-ionis-pharmaceuticals-inc-2018-01-22", "https://www.nasdaq.com/articles/biotech-tide-turning-2018-01-05", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-vb-alny-cgnx-csgp-2018-01-03", "https://www.nasdaq.com/articles/3-top-value-stocks-buy-2018-2017-12-31", "https://www.nasdaq.com/articles/5-best-performing-biotech-stocks-2017-2017-12-28", "https://www.nasdaq.com/articles/4-biotech-stocks-that-more-than-doubled-this-year-2017-12-22", "https://www.nasdaq.com/articles/why-alnylam-pharmaceuticals-soared-249-2017-2018-01-10", "https://www.nasdaq.com/articles/regeneron-sanofi-expand-investment-in-cemiplimab-dupilumab-2018-01-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-label-expansion-exelixiss-cabometyx-fda-nod-sparks-gene-therapy-2017", "https://www.nasdaq.com/articles/alnylam-sanofi-submit-maa-in-europe-for-rnai-candidate-2017-12-19", "https://www.nasdaq.com/articles/sanofi-alnylam-say-fda-lifts-clinical-hold-on-fitusiran-2017-12-18", "https://www.nasdaq.com/articles/fda-just-blessed-hemophilia-trial-biotech-2017-12-15", "https://www.nasdaq.com/articles/health-care-sector-update-12152017-jnj-pfe-abt-mrk-amgn-alny-nvo-sgry-rigl-teva-2017-12-15", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-vbk-alny-cgnx-xpo-2017-12-21", "https://www.nasdaq.com/articles/vbk-ttwo-cgnx-alny-etf-inflow-alert-2017-12-13", "https://www.nasdaq.com/articles/why-alnylam-pharmaceuticals-rose-127-november-2017-12-06", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-xbi-alny-juno-srpt-2017-12-05", "https://www.nasdaq.com/articles/alny-crosses-above-average-analyst-target-2017-12-04", "https://www.nasdaq.com/articles/why-medicines-co-tumbling-despite-270-million-deal-2017-11-29", "https://www.nasdaq.com/articles/heres-how-alnylam-pharmaceuticals-inc-crushed-it-2017-2017-11-29", "https://www.nasdaq.com/articles/commit-buy-alnylam-pharmaceuticals-70-earn-114-using-options-2017-11-28", "https://www.nasdaq.com/articles/alnylam-gets-some-welcome-news-2017-12-15", "https://www.nasdaq.com/articles/opus-point-partners-management-llc-buys-bioverativ-inc-acadia-pharmaceuticals-inc-united", "https://www.nasdaq.com/articles/alnylam-starts-rolling-nda-submission-for-rnai-candidate-2017-11-17", "https://www.nasdaq.com/articles/why-is-alnylams-alny-stock-up-more-than-200-this-year-2017-11-16", "https://www.nasdaq.com/articles/spdr-sp-biotech-etf-experiences-big-outflow-2017-11-16", "https://www.nasdaq.com/articles/health-care-sector-update-11162017-alny-2017-11-16", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-incs-pipeline-progresses-approval-next-2017-11-15", "https://www.nasdaq.com/articles/alnylam-rnai-drug-gets-accelerated-assessment-grant-from-ema-2017-11-14", "https://www.nasdaq.com/articles/alnylams-rnai-candidate-gains-breakthrough-therapy-status-2017-11-21", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-inc-sets-itself-growth-2017-11-14", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-earnings-results-fuel-volatility-2017-11-10", "https://www.nasdaq.com/articles/alnylams-alny-q3-earnings-revenues-miss-estimates-2017-11-08", "https://www.nasdaq.com/articles/how-invest-biotech-stocks-2017-11-08", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-xbi-alny-pbyi-sgen-2017-11-07", "https://www.nasdaq.com/articles/after-hours-earnings-report-november-7-2017-mar-etp-ete-clr-agu-alny-xec-ttwo-dva-jkhy", "https://www.nasdaq.com/articles/whats-in-store-for-catalyst-cprx-this-earnings-season-2017-11-06", "https://www.nasdaq.com/articles/pre-market-most-active-nov-14-2017-bndx-roku-dks-hmc-ge-tvix-phg-golf-jd-hd-qqq-alny-2017", "https://www.nasdaq.com/articles/whats-in-store-for-ligand-lgnd-this-earnings-season-2017-11-06", "https://www.nasdaq.com/articles/whats-in-store-for-madrigal-mdgl-this-earnings-season-2017-11-06", "https://www.nasdaq.com/articles/inovio-ino-q3-earnings%3A-is-a-beat-in-store-for-the-stock-2017-11-06", "https://www.nasdaq.com/articles/ionis-rebounds-after-beating-alnylam-drug-application-europe-2017-11-03", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-soars%3A-stock-adds-10.3-in-session-2017-11-03", "https://www.nasdaq.com/articles/alnylam-spikes-prodding-ionis-pitfall-rare-disease-drug-trial-2017-11-02", "https://www.nasdaq.com/articles/heres-why-alnylams-gain-ionis-pharmaceuticals-loss-today-2017-11-02", "https://www.nasdaq.com/articles/is-a-surprise-coming-for-alnylam-pharmaceuticals-alny-this-earnings-season-2017-11-06", "https://www.nasdaq.com/articles/biotechs-lead-health-sector-are-those-glory-days-over-2017-10-30", "https://www.nasdaq.com/articles/how-celgene-gileads-pricing-woes-continue-haunt-biotech-stocks-2017-10-30", "https://www.nasdaq.com/articles/medicines-company-mdco-reports-q3-loss-revenues-miss-2017-10-26", "https://www.nasdaq.com/articles/xbi-alny-clvs-sgen-etf-outflow-alert-2017-10-23", "https://www.nasdaq.com/articles/spdr-sp-biotech-etf-experiences-big-outflow-2017-10-13", "https://www.nasdaq.com/articles/xlf-fny-big-etf-inflows-2017-10-06", "https://www.nasdaq.com/articles/heres-why-alnylam-pharmaceuticals-rallied-327-september-2017-10-05", "https://www.nasdaq.com/articles/xbi-alny-pbyi-sgen-etf-inflow-alert-2017-10-31", "https://www.nasdaq.com/articles/analysts-act-health-care-stocks-2017-10-03", "https://www.nasdaq.com/articles/3-biotech-stocks-skyrocketed-week-can-they-go-higher-2017-09-23", "https://www.nasdaq.com/articles/alnylam-sanofis-rnai-drug-meets-endpoint-in-study-stock-up-2017-09-21", "https://www.nasdaq.com/articles/company-news-for-sep-21-2017-2017-09-21", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-soars%3A-stock-adds-51.7-in-session-2017-09-21", "https://www.nasdaq.com/articles/wednesdays-etf-unusual-volume-fnx-2017-09-20", "https://www.nasdaq.com/articles/whats-next-alnylam-pharmaceuticals-inc-2017-09-20", "https://www.nasdaq.com/articles/fxh-alny-algn-gild-large-inflows-detected-etf-2017-10-04", "https://www.nasdaq.com/articles/calamities-couldnt-spoil-the-bullish-run-2017-09-20", "https://www.nasdaq.com/articles/hurricanes-earthquakes-and-record-high-markets-2017-09-20", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-lower-general-mills-earnings-miss-estimates-2017-09", "https://www.nasdaq.com/articles/pre-market-most-active-sep-20-2017-nbrv-fwonk-bbby-alny-chu-rad-db-mu-wdc-teva-s-bbu-2017", "https://www.nasdaq.com/articles/what-happened-stock-market-today-2017-09-20", "https://www.nasdaq.com/articles/heres-why-arbutus-biopharma-corp-stock-soared-today-2017-09-20", "https://www.nasdaq.com/articles/close-update-dow-sp-500-hit-records-wobbly-session-sees-financials-gain-after-fed-2017-09", "https://www.nasdaq.com/articles/mid-day-market-update-bed-bath-beyond-drops-earnings-miss-delmar-pharmaceuticals-shares", "https://www.nasdaq.com/articles/calamities-couldnt-spoil-the-bullish-run-2017-09-20", "https://www.nasdaq.com/articles/hurricanes-earthquakes-and-record-high-markets-2017-09-20", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc.-alny-stock-soars-on-drug-breakthrough-2017-09-20", "https://www.nasdaq.com/articles/billionaire-george-soros-fund-bought-these-3-pharma-stocks-should-you-2017-09-18", "https://www.nasdaq.com/articles/notable-friday-option-activity-alny-cva-twtr-2017-09-15", "https://www.nasdaq.com/articles/alnylam-shares-plunge-on-patient-death-dosing-suspended-2017-09-08", "https://www.nasdaq.com/articles/heres-why-alnylam-pharmaceuticals-inc-slipping-today-2017-09-07", "https://www.nasdaq.com/articles/mid-afternoon-market-update-crude-oil-over-2-alnylam-pharma-shares-climb-after-positive", "https://www.nasdaq.com/articles/pre-market-most-active-sep-7-2017-cab-bldr-gpro-tvix-irt-ge-insm-azn-wll-bac-alny-qqq-2017", "https://www.nasdaq.com/articles/what-happened-stock-market-today-2017-09-07", "https://www.nasdaq.com/articles/health-care-sector-update-09072017-sgrynlnkalny-2017-09-07", "https://www.nasdaq.com/articles/health-care-sector-update-09072017-ekso-nlnk-alny-2017-09-07", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-pii-alny-gpi-2017-09-06", "https://www.nasdaq.com/articles/4-biotech-stocks-more-doubled-year-2017-09-05", "https://www.nasdaq.com/articles/alny-crosses-above-average-analyst-target-2017-09-04", "https://www.nasdaq.com/articles/morning-movers-barnes-noble-sinks-earnings-hertz-jumps-2017-09-07", "https://www.nasdaq.com/articles/the-medicines-cos-inclisiran-positive-in-extension-study-2017-08-29", "https://www.nasdaq.com/articles/sangamo-therapeutics-initiates-dosing-in-hemophilia-a-study-2017-08-28", "https://www.nasdaq.com/articles/3-biotech-stocks-could-soar-september-2017-08-27", "https://www.nasdaq.com/articles/mondays-etf-unusual-volume-bbh-2017-08-21", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-retains-rights-to-inotersen-stock-up-2017-08-14", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-earnings-waiting-apollo-2017-08-14", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-inc-growing-royalties-advancing-pipeline-and-getting-back-rights", "https://www.nasdaq.com/articles/4-biotech-stocks-that-more-than-doubled-this-year-2017-09-01", "https://www.nasdaq.com/articles/the-medicines-company-mdco-q2-loss-widens-revenues-miss-2017-08-10", "https://www.nasdaq.com/articles/after-hours-earnings-report-august-9-2017-ntes-mfc-foxa-slf-agu-lyv-uhal-alny-midd-gxp", "https://www.nasdaq.com/articles/3-drug-stocks-poised-to-surpass-estimates-in-q2-earnings-2017-08-08", "https://www.nasdaq.com/articles/arena-pharmaceuticals-arna-q2-loss-wider-than-expected-2017-08-08", "https://www.nasdaq.com/articles/why-alnylam-pharmaceuticals-alny-might-surprise-this-earnings-season-2017-08-08", "https://www.nasdaq.com/articles/zoetis-zts-beats-on-q2-earnings-sales-ups-2017-view-2017-08-08", "https://www.nasdaq.com/articles/endo-endp-beats-q2-earnings-sales-2017-guidance-lowered-2017-08-08", "https://www.nasdaq.com/articles/alnylam-alny-q2-loss-narrower-than-expected-sales-miss-2017-08-10", "https://www.nasdaq.com/articles/alnylam-alny-upgraded-to-buy-on-solid-pipeline-growth-2017-07-12", "https://www.nasdaq.com/articles/alnylam-alny-stock-down-despite-positive-hemophilia-data-2017-07-11", "https://www.nasdaq.com/articles/alnylam-commences-phase-iii-study-for-hemophilia-candidate-2017-07-10", "https://www.nasdaq.com/articles/are-medicines-companys-key-drugs-set-for-growth-in-2017-2017-07-10", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-stock-perked-14-june-heres-why-2017-07-07", "https://www.nasdaq.com/articles/biotech-stock-roundup-eu-nod-regeneron-ra-drug-portola-soars-fda-nod-2017-06-29", "https://www.nasdaq.com/articles/3-pivotal-drug-trials-watch-explosive-potential-2017-06-29", "https://www.nasdaq.com/articles/alny-crosses-above-average-analyst-target-2017-07-21", "https://www.nasdaq.com/articles/5-best-biotech-stocks-2017-so-far-2017-06-25", "https://www.nasdaq.com/articles/why-is-alnylams-alny-stock-close-to-100-this-year-2017-06-15", "https://www.nasdaq.com/articles/alnylam-still-has-lot-upside-bhavneesh-sharmas-idea-month-2017-06-11", "https://www.nasdaq.com/articles/why-is-alnylam-alny-up-31.2-since-the-last-earnings-report-2017-06-08", "https://www.nasdaq.com/articles/thursday-61-insider-buying-report-pbf-alny-2017-06-01", "https://www.nasdaq.com/articles/alnylams-givosiran-gets-breakthrough-therapy-status-by-fda-2017-06-01", "https://www.nasdaq.com/articles/commit-buy-alnylam-pharmaceuticals-50-earn-18-annualized-using-options-2017-05-26", "https://www.nasdaq.com/articles/5-biotech-stocks-major-catalysts-july-2017-06-28", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-progressing-well-on-pipeline-2017-05-25", "https://www.nasdaq.com/articles/pre-market-most-active-may-24-2017-now-fgl-glyc-fcau-ino-low-stng-bac-nvda-ttd-qqq-alny", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-reaches-analyst-target-price-2017-05-17", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-looks-good%3A-stock-jumps-16.3-2017-05-16", "https://www.nasdaq.com/articles/why-ionis-pharmaceuticals-inc-tanked-and-alnylam-pharmaceuticals-inc-soaring-today-2017-05", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-aap-wlb-alny-2017-05-15", "https://www.nasdaq.com/articles/pre-market-most-active-may-15-2017-pthn-san-bp-nok-snap-stm-feye-ions-aapl-tsla-alny-jive", "https://www.nasdaq.com/articles/regeneron-presents-positive-phase-ii-data-on-hofh-candidate-2017-05-25", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-progressing-well-on-pipeline-2017-05-25", "https://www.nasdaq.com/articles/health-care-sector-update-05052017-alny-2017-05-05", "https://www.nasdaq.com/articles/earnings-reaction-history-alnylam-pharmaceuticals-inc-400-follow-through-indicator-76", "https://www.nasdaq.com/articles/pre-market-earnings-report-may-5-2017-ci-trp-ctsh-hcn-mco-cnp-bpl-jll-snh-cfx-alny-vwr", "https://www.nasdaq.com/articles/the-medicines-company-mdco-q1-loss-wider-than-expected-2017-04-27", "https://www.nasdaq.com/articles/alny-makes-bullish-cross-above-critical-moving-average-2017-04-26", "https://www.nasdaq.com/articles/5-reasons-why-sanofi-sny-is-a-good-stock-to-buy-now-2017-04-12", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-earnings-all-eyes-apollo-2017-05-10", "https://www.nasdaq.com/articles/5-deadliest-diseases-us-and-top-drugs-potentially-way-treat-them-2017-04-02", "https://www.nasdaq.com/articles/3-best-cholesterol-drug-stocks-buy-2017-2017-03-30", "https://www.nasdaq.com/articles/how-company-taking-amgen-2017-03-23", "https://www.nasdaq.com/articles/alnylam-alny-up-14.5-since-earnings-report%3A-can-it-continue-2017-03-23", "https://www.nasdaq.com/articles/alnylams-ldl-lowering-drug-positive-in-phase-ii-study-2017-03-20", "https://www.nasdaq.com/articles/better-buy-bluebird-bio-inc-vs-alnylam-pharmaceuticals-2017-02-28", "https://www.nasdaq.com/articles/heres-why-alnylam-pharmaceuticals-inc-stock-bounced-101-today-2017-02-27", "https://www.nasdaq.com/articles/regenerons-evinacumab-gets-breakthrough-therapy-by-fda-2017-04-07", "https://www.nasdaq.com/articles/fbt-acad-alny-kite-etf-outflow-alert-2017-02-21", "https://www.nasdaq.com/articles/better-buy-alnylam-pharmaceuticals-inc-vs-biomarin-pharmaceutical-inc-2017-02-20", "https://www.nasdaq.com/articles/alnylam-alny-q3-loss-narrower-than-expected-revenues-rise-2017-02-09", "https://www.nasdaq.com/articles/thursdays-etf-movers-xbi-gdx-2017-02-09", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-presents-progress-investors-dig-it-2017-02-09", "https://www.nasdaq.com/articles/better-buy-agenus-inc-vs-alnylam-pharmaceuticals-inc-2017-02-06", "https://www.nasdaq.com/articles/why-medicines-company-rocketed-higher-today-2017-02-03", "https://www.nasdaq.com/articles/commit-purchase-alnylam-pharmaceuticals-35-earn-209-annualized-using-options-2017-02-23", "https://www.nasdaq.com/articles/mid-afternoon-market-update-derma-sciences-climbs-acquisition-news-novadaq-shares-plunge", "https://www.nasdaq.com/articles/wednesdays-etf-movers-oih-xbi-2017-01-11", "https://www.nasdaq.com/articles/wednesday-sector-laggards-drugs-biotechnology-stocks-2017-01-11", "https://www.nasdaq.com/articles/the-medicines-co-ldl-lowering-drug-positive-in-phase-ii-2017-01-09", "https://www.nasdaq.com/articles/why-alnylam-pharmaceuticals-inc.-stock-is-a-2017-winner-alny-2017-01-09", "https://www.nasdaq.com/articles/heres-why-alnylam-pharmaceuticals-plunged-598-2016-2017-01-07", "https://www.nasdaq.com/articles/winning-pharmaceutical-stock-2017-2017-01-06", "https://www.nasdaq.com/articles/implied-analyst-12-month-target-pbe-2017-01-24", "https://www.nasdaq.com/articles/better-buy-alnylam-pharmaceuticals-vs-ionis-pharmaceuticals-2016-12-31", "https://www.nasdaq.com/articles/why-cliffs-natural-resources-groupon-and-alnylam-pharmaceuticals-slumped-today-2016-12-29", "https://www.nasdaq.com/articles/better-buy-juno-therapeutics-vs-alnylam-pharmaceuticals-2016-12-17", "https://www.nasdaq.com/articles/2-reasons-why-alnylam-pharmaceuticals-stock-gained-185-november-2016-12-07", "https://www.nasdaq.com/articles/3-things-you-need-know-about-ionis-pharmaceuticals-pipeline-2016-12-01", "https://www.nasdaq.com/articles/commit-buy-alnylam-pharmaceuticals-35-earn-191-using-options-2016-11-22", "https://www.nasdaq.com/articles/analysts-forecast-20-gains-ahead-holdings-fbt-2016-11-17", "https://www.nasdaq.com/articles/health-care-sector-update-01062017-mdco-sny-regn-jnj-pfe-abt-mrk-amgn-2017-01-06", "https://www.nasdaq.com/articles/why-these-biotechs-saw-double-digit-gains-today-2016-11-09", "https://www.nasdaq.com/articles/why-alnylam-pharmaceuticals-inc-took-475-dive-october-2016-11-07", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-discloses-deaths-waits-more-data-2016-11-04", "https://www.nasdaq.com/articles/fridays-etf-unusual-volume-bbh-2016-11-04", "https://www.nasdaq.com/articles/alnylam-alny-q3-loss-wider-than-expected-revenues-up-2016-11-03", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-slid-126-today-after-earnings-2016-11-03", "https://www.nasdaq.com/articles/the-medicines-co.-reports-positive-phase-ii-data-on-pcsk9si-2016-10-19", "https://www.nasdaq.com/articles/sanofi-opts-into-alnylams-fitusiran-hemophilia-program-in-u.s.-2016-11-15", "https://www.nasdaq.com/articles/surprising-analyst-12-month-target-fbt-2016-10-17", "https://www.nasdaq.com/articles/alnylam-alny-to-continue-phase-iii-study-on-patisiran-2016-10-12", "https://www.nasdaq.com/articles/biotech-stock-roundup-alnylam-slumps-revusiran-update-tesaro-impresses-esmo-2016-10-12", "https://www.nasdaq.com/articles/better-buy-alnylam-pharmaceuticals-inc-vs-sarepta-therapeutics-inc-2016-10-10", "https://www.nasdaq.com/articles/kamada-kmda-extends-partnership-with-shire-for-glassia-2016-10-10", "https://www.nasdaq.com/articles/whats-next-alnylam-pharmaceuticals-inc-after-its-phase-3-failure-2016-10-07", "https://www.nasdaq.com/articles/alnylams-rnai-failure-could-catch-monsanto-investors-guard-2016-10-07", "https://www.nasdaq.com/articles/monday-1017-insider-buying-report-alny-rhp-2016-10-17", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-yum-brands-sales-miss-estimates-2016-10-06", "https://www.nasdaq.com/articles/why-alnylam-pharmaceuticals-getting-crushed-today-2016-10-06", "https://www.nasdaq.com/articles/alnylam-alny-discontinues-phase-iii-study-on-revusiran-2016-10-06", "https://www.nasdaq.com/articles/pre-market-most-active-oct-6-2016-twtr-klac-auph-sny-crm-alny-rdsb-nok-lrcx-wmt-mdco-jd", "https://www.nasdaq.com/articles/health-care-sector-update-10062016-pfephmdalny-2016-10-06", "https://www.nasdaq.com/articles/mid-afternoon-market-update-crude-oil-15-alnylam-pharma-shares-tumble-revusiran", "https://www.nasdaq.com/articles/health-care-sector-update-10062016-scyx-phmd-alny-slrc-2016-10-06", "https://www.nasdaq.com/articles/mid-day-market-update-aurinia-pharmaceuticals-gains-aurion-data-twitter-shares-slide-2016", "https://www.nasdaq.com/articles/mid-day-market-update-crude-oil-rises-over-2-intra-cellular-therapies-shares-slide-2016-09", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-lower-pepsico-beats-q3-expectations-2016-09-29", "https://www.nasdaq.com/articles/better-buy-ziopharm-oncology-inc-vs-alnylam-pharmaceuticals-inc-2016-09-24", "https://www.nasdaq.com/articles/3-ways-ionis-pharmaceuticals-inc-beating-competition-2016-09-19", "https://www.nasdaq.com/articles/alnylam-alny-reports-positive-phase-i-data-on-aln-as1-2016-09-08", "https://www.nasdaq.com/articles/better-buy-alnylam-pharmaceuticals-inc-vs-ionis-pharmaceuticals-2016-09-02", "https://www.nasdaq.com/articles/notable-monday-option-activity-srpt-alny-swft-2016-08-22", "https://www.nasdaq.com/articles/why-medicines-companys-share-price-got-sick-today-2016-10-06", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-shares-march-higher-can-it-continue-2016-08-10", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-breaks-above-200-day-moving-average-bullish-alny-2016-08-04", "https://www.nasdaq.com/articles/why-alnylam-pharmaceuticals-inc-stock-gained-108-july-2016-08-04", "https://www.nasdaq.com/articles/earnings-reaction-history-alnylam-pharmaceuticals-inc-500-follow-through-indicator-61", "https://www.nasdaq.com/articles/5-drug-stocks-to-watch-for-earnings-on-aug-4%3A-bmrn-more-2016-08-03", "https://www.nasdaq.com/articles/7-biotech-stocks-pivotal-catalysts-2017-2016-08-02", "https://www.nasdaq.com/articles/health-care-sector-update-07252016-alnybindtbra-2016-07-25", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-cranks-out-data-2016-08-12", "https://www.nasdaq.com/articles/us-stocks-extend-gains-following-better-expected-jobs-report-2016-07-08", "https://www.nasdaq.com/articles/better-buy-alnylam-pharmaceuticals-inc-vs-incyte-2016-07-07", "https://www.nasdaq.com/articles/alnylam-stock-up-on-favorable-patisiran-and-revusiran-data-2016-07-05", "https://www.nasdaq.com/articles/better-buy-ionis-pharmaceuticals-vs-alnylam-pharmaceuticals-2016-07-05", "https://www.nasdaq.com/articles/why-alnylam-pharmaceuticals-inc-down-373-year-2016-07-05", "https://www.nasdaq.com/articles/why-alnylam-pharmaceuticals-inc-jumped-107-friday-2016-07-01", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-july-2016-06-25", "https://www.nasdaq.com/articles/alnylam-alny-begins-phase-i-ii-study-on-chronic-hbv-drug-2016-07-08", "https://www.nasdaq.com/articles/could-alnylam-pharmaceuticals-change-medicine-we-know-it-2016-05-31", "https://www.nasdaq.com/articles/ionis-down-glaxo-dumps-ionis-ttrrx-phase-iii-study-plans-2016-05-27", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-in-focus%3A-stock-rises-9.9-2016-05-26", "https://www.nasdaq.com/articles/why-alnylam-pharmaceuticals-inc-competed-higher-today-2016-05-26", "https://www.nasdaq.com/articles/better-buy-alnylam-pharmaceuticals-inc-vs-ionis-pharmaceuticals-inc-2016-05-24", "https://www.nasdaq.com/articles/drawing-biopharma-concepts-crayon-2016-05-23", "https://www.nasdaq.com/articles/vivus-vvus-q1-loss-narrower-qsymia-sales-decline-2016-05-04", "https://www.nasdaq.com/articles/fbts-underlying-holdings-could-mean-28-gain-potential-2016-06-13", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-incs-double-digit-earnings-fall-2016-05-04", "https://www.nasdaq.com/articles/alnylam-alny-reports-wider-than-expected-loss-in-q1-2016-05-03", "https://www.nasdaq.com/articles/better-buy-alnylam-pharmaceuticals-inc-vs-sarepta-2016-05-02", "https://www.nasdaq.com/articles/after-hours-earnings-report-may-2-2016-aig-apc-ggp-eix-vno-sbac-exr-ugi-are-afg-fmc-alny", "https://www.nasdaq.com/articles/regenerons-bold-bet-future-medicine-2016-04-12", "https://www.nasdaq.com/articles/how-pieces-add-iyh-targets-170-2016-04-07", "https://www.nasdaq.com/articles/better-buy-bluebird-bio-inc-vs-alnylam-pharmaceuticals-2016-04-06", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-alny-zg-scty-2016-05-04", "https://www.nasdaq.com/articles/biomarin-bmrn-bmn-270-gets-orphan-drug-status-in-eu-2016-03-28", "https://www.nasdaq.com/articles/bayers-kovaltry-gets-approval-in-the-u.s.-for-hemophilia-a-2016-03-18", "https://www.nasdaq.com/articles/alnylam-director-buys-2000-shares-2016-03-14", "https://www.nasdaq.com/articles/alnylam-begins-study-for-primary-hyperoxaluria-type-1-2016-03-10", "https://www.nasdaq.com/articles/can-conatus-cnat-surprise-estimates-in-q4-earnings-2016-03-07", "https://www.nasdaq.com/articles/better-buy-juno-therapeutics-vs-alnylam-pharmaceuticals-2016-02-23", "https://www.nasdaq.com/articles/why-bluebird-bio-inc-juno-therapeutics-inc-and-alnylam-pharmaceuticals-inc-jumped-today", "https://www.nasdaq.com/articles/thursdays-etf-movers-fbt-kre-2016-03-31", "https://www.nasdaq.com/articles/biomarin-bmrn-bmn-270-gets-orphan-drug-status-in-eu-2016-03-28", "https://www.nasdaq.com/articles/bayers-kovaltry-gets-approval-in-the-u.s.-for-hemophilia-a-2016-03-18", "https://www.nasdaq.com/articles/alnylam-director-buys-2000-shares-2016-03-14", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-incs-most-important-slide-2016-01-19", "https://www.nasdaq.com/articles/alnylam-provides-update-on-rnai-therapeutics-pipeline-2016-01-13", "https://www.nasdaq.com/articles/behind-alnylam-pharmaceuticals-december-plunge-2016-01-09", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-waiting-apollo-2016-02-16", "https://www.nasdaq.com/articles/alnylam-initiates-final-part-of-phase-i-ii-study-on-aln-cc5-2015-12-18", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-glng-elli-alny-2015-12-17", "https://www.nasdaq.com/articles/will-2016-be-alnylam-pharmaceuticals-incs-best-year-yet-2015-12-14", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-selling-today-why-2015-12-07", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-stock-picked-steam-november-any-upside-remaining-2015-12-07", "https://www.nasdaq.com/articles/first-week-alny-january-2016-options-trading-2015-12-01", "https://www.nasdaq.com/articles/novembers-best-sector-etfs-2015-12-01", "https://www.nasdaq.com/articles/alnylam-submits-clinical-trial-application-for-aln-go1-in-uk-2015-12-22", "https://www.nasdaq.com/articles/weekly-insider-sells-highlights-facebook-pacwest-bancorp-waste-management-alnylam-2015-11", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-earnings-100-positive-data-2015-11-15", "https://www.nasdaq.com/articles/these-2-companies-could-revolutionize-heart-disease-prevention-2015-11-14", "https://www.nasdaq.com/articles/alnylam-alny-reports-positive-interim-data-on-aln-pcssc-2015-11-12", "https://www.nasdaq.com/articles/alnylam-q3-loss-narrower-than-expected-revenues-miss-2015-11-10", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-shares-cross-above-200-dma-2015-11-09", "https://www.nasdaq.com/articles/is-intrexon-xon-likely-to-disappoint-this-earnings-season-2015-11-06", "https://www.nasdaq.com/articles/these-3-biotechs-are-winning-clinic-2015-11-20", "https://www.nasdaq.com/articles/will-puma-biotechnology-pbyi-surprise-in-q3-earnings-2015-11-06", "https://www.nasdaq.com/articles/will-merrimack-mack-surprise-estimates-in-q3-earnings-2015-11-06", "https://www.nasdaq.com/articles/will-intercept-icpt-beat-estimates-in-q3-earnings-2015-11-06", "https://www.nasdaq.com/articles/catalyst-pharmaceutical-cprx%3A-a-peek-into-q3-earnings-2015-11-06", "https://www.nasdaq.com/articles/will-inovio-ino-disappoint-investors-this-earnings-season-2015-11-06", "https://www.nasdaq.com/articles/will-biodelivery-bdsi-disappoint-estimates-in-q3-earnings-2015-11-05", "https://www.nasdaq.com/articles/whats-in-store-for-repros-rprx-this-earnings-season-2015-11-05", "https://www.nasdaq.com/articles/pre-market-earnings-report-november-9-2015-pcln-dish-amg-alny-wwav-isis-comm-sni-icpt-hpt", "https://www.nasdaq.com/articles/horizon-hznp%3A-whats-in-store-this-earnings-season-2015-11-04", "https://www.nasdaq.com/articles/will-agios-agio-disappoint-investors-this-earnings-season-2015-11-04", "https://www.nasdaq.com/articles/synta-snta-q3-earnings-preview%3A-whats-in-the-cards-2015-11-03", "https://www.nasdaq.com/articles/can-endo-internationals-endp-q3-earnings-surprise-2015-11-03", "https://www.nasdaq.com/articles/will-aveo-aveo-pull-a-surprise-this-earnings-season-2015-11-02", "https://www.nasdaq.com/articles/whats-in-store-for-conatus-cnat-this-earnings-season-2015-11-02", "https://www.nasdaq.com/articles/what-to-expect-from-radius-rdus-this-earnings-season-2015-11-02", "https://www.nasdaq.com/articles/celgene-celg-to-report-q3-earnings%3A-what-to-expect-2015-11-04", "https://www.nasdaq.com/articles/whats-store-regeneron-regn-earnings-season-2015-11-02", "https://www.nasdaq.com/articles/whats-in-the-cards-for-zoetis-zts-this-earnings-season-2015-11-02", "https://www.nasdaq.com/articles/health-care-sector-update-10232015-cyad-rare-alny-2015-10-23", "https://www.nasdaq.com/articles/alnylam-offers-data-on-aln-ttrsc02-platform-technology-2015-10-15", "https://www.nasdaq.com/articles/health-care-sector-update-10132015-alnyimnphtwr-2015-10-13", "https://www.nasdaq.com/articles/alnylam-initiates-extension-study-on-aln-at3-for-hemophilia-2015-10-09", "https://www.nasdaq.com/articles/sanofi-opts-into-alnylams-aln-at3-hemophilia-program-2015-10-02", "https://www.nasdaq.com/articles/whats-in-store-for-endocyte-ecyt-this-earnings-season-2015-11-02", "https://www.nasdaq.com/articles/first-week-alny-november-20th-options-trading-2015-09-24", "https://www.nasdaq.com/articles/alnylam-reports-positive-initial-phase-i-data-on-aln-as1-2015-09-16", "https://www.nasdaq.com/articles/alnylam-to-speed-up-development-for-primary-hyperoxaluria-2015-09-09", "https://www.nasdaq.com/articles/pcsk9-drugs-are-here-and-way-over-there-2015-09-04", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-ariad-celgene-amicus-and-alnylam-2015-09-03", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-news-ariad-takeover-target-2015-09-02", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-falls%3A-stock-goes-down-5.7-2015-09-01", "https://www.nasdaq.com/articles/alnylams-extension-study-on-patisiran-reveals-positive-data-2015-09-29", "https://www.nasdaq.com/articles/first-week-october-16th-options-trading-alnylam-pharmaceuticals-alny-2015-08-31", "https://www.nasdaq.com/articles/health-care-sector-update-08312015-alny-mdco-blfs-fold-2015-08-31", "https://www.nasdaq.com/articles/alnylam-presents-positive-data-on-pcsk9-synthesis-inhibitor-2015-08-31", "https://www.nasdaq.com/articles/heres-why-alnylam-pharmaceuticals-stock-crashed-today-2015-08-07", "https://www.nasdaq.com/articles/alny-crosses-below-key-moving-average-level-2015-08-07", "https://www.nasdaq.com/articles/alnylams-q2-loss-wider-than-expected-revenues-fall-short-analyst-blog-2015-08-07", "https://www.nasdaq.com/articles/after-hours-earnings-report-august-6-2015-eog-mnst-ed-mhk-nvda-alny-pba-mdvn-anac-nuan", "https://www.nasdaq.com/articles/why-medicines-companys-stock-broke-out-today-2015-08-31", "https://www.nasdaq.com/articles/first-week-october-16th-options-trading-alnylam-pharmaceuticals-alny-2015-08-31", "https://www.nasdaq.com/articles/health-care-sector-update-08312015-alny-mdco-blfs-fold-2015-08-31", "https://www.nasdaq.com/articles/alnylam-reports-encouraging-new-data-on-hemophilia-drug-analyst-blog-2015-06-24", "https://www.nasdaq.com/articles/insiders-seeing-green-alny-new-52-week-high-2015-06-18", "https://www.nasdaq.com/articles/alnylam-reveals-positive-initial-data-on-rnai-drug-aln-cc5-analyst-blog-2015-06-15", "https://www.nasdaq.com/articles/health-care-sector-update-06112015-drnaalnymrkptbipbmd-2015-06-11", "https://www.nasdaq.com/articles/first-week-march-2016-options-trading-alnylam-pharmaceuticals-alny-2015-07-27", "https://www.nasdaq.com/articles/health-care-sector-update-06112015-axondrnaalnyptbi-2015-06-11", "https://www.nasdaq.com/articles/why-shares-regulus-therapeutics-inc-are-tumbling-2015-06-02", "https://www.nasdaq.com/articles/alnylam-alny-begins-phase-i-study-on-liver-disease-drug-analyst-blog-2015-05-27", "https://www.nasdaq.com/articles/alnylams-cardiac-amyloidosis-drug-gets-orphan-status-analyst-blog-2015-05-22", "https://www.nasdaq.com/articles/alnylam-files-clinical-trial-application-for-aln-aat-analyst-blog-2015-05-18", "https://www.nasdaq.com/articles/alnylams-q1-loss-narrower-than-expected-confirms-guidance-analyst-blog-2015-05-08", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-incs-five-year-plan-2015-05-08", "https://www.nasdaq.com/articles/use-options-chance-buy-alny-35-discount-2015-06-11", "https://www.nasdaq.com/articles/3-biotech-stocks-still-attractive-after-mondays-sell-off-analyst-blog-2015-04-28", "https://www.nasdaq.com/articles/use-options-chance-buy-alny-32-discount-2015-04-23", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-medicines-athersys-and-alnylam-press-releases", "https://www.nasdaq.com/articles/can-the-rally-in-alnylam-pharmaceuticals-alny-shares-continue-tale-of-the-tape-2015-04-22", "https://www.nasdaq.com/articles/alnylam-reports-positive-patisiran-results-shares-up-analyst-blog-2015-04-22", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-starts-earnings-season-strong-note-setbacks-ampio-athersys", "https://www.nasdaq.com/articles/why-alnylam-pharmaceuticals-inc-shares-are-soaring-today-2015-04-21", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-celladon-amgen-biogen-and-alnylam-pharmaceuticals-press", "https://www.nasdaq.com/articles/why-alnylam-pharmaceuticals-alny-stock-might-be-a-great-pick-tale-of-the-tape-2015-04-09", "https://www.nasdaq.com/articles/infinity-pharmaceuticals-exercises-duvelisib-royalty-option-analyst-blog-2015-04-01", "https://www.nasdaq.com/articles/hospira-presents-data-on-retacrit-an-epogen-biosimilar-analyst-blog-2015-03-30", "https://www.nasdaq.com/articles/interesting-alny-put-and-call-options-may-15th-2015-03-25", "https://www.nasdaq.com/articles/use-options-chance-buy-alny-30-discount-2015-03-25", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-if-sector-crashes-2015-03-23", "https://www.nasdaq.com/articles/alnylam-announces-positive-data-from-natural-history-study-analyst-blog-2015-03-16", "https://www.nasdaq.com/articles/alnylam-reports-publication-of-new-data-on-hemophilia-drug-analyst-blog-2015-04-14", "https://www.nasdaq.com/articles/vanda-down-after-candidate-disappoints-in-phase-ii-study-analyst-blog-2015-03-09", "https://www.nasdaq.com/articles/mylan-beats-on-q4-earnings-2015-guidance-encouraging-analyst-blog-2015-03-03", "https://www.nasdaq.com/articles/qlt-qlti-reports-wider-year-over-year-loss-in-q4-analyst-blog-2015-03-02", "https://www.nasdaq.com/articles/endo-endp-beats-q4-earnings-announces-divestments-analyst-blog-2015-03-02", "https://www.nasdaq.com/articles/amgens-kyprolis-fares-better-velcade-study-analyst-blog-2015-03-02", "https://www.nasdaq.com/articles/whoa-profit-isis-pharmaceuticals-inc-2015-02-28", "https://www.nasdaq.com/articles/aegerions-q4-loss-narrows-y-y-ups-juxtapid-sales-view-analyst-blog-2015-02-27", "https://www.nasdaq.com/articles/alnylam-alny-shares-march-higher-can-it-continue-tale-of-the-tape-2015-03-13", "https://www.nasdaq.com/articles/pharmacyclics-misses-on-q4-earnings-reiterates-2015-view-analyst-blog-2015-02-19", "https://www.nasdaq.com/articles/theravance-reports-in-line-loss-in-q4-revenues-increase-analyst-blog-2015-02-19", "https://www.nasdaq.com/articles/company-news-for-february-17-2015-corporate-summary-2015-02-17", "https://www.nasdaq.com/articles/actelions-aliof-earnings-revenues-fall-y-y-in-q4-analyst-blog-2015-02-17", "https://www.nasdaq.com/articles/hospira-launches-inflectra-remicade-biosimilar-in-europe-analyst-blog-2015-02-17", "https://www.nasdaq.com/articles/emergent-biosolutions-reports-positive-data-on-biothrax-analyst-blog-2015-02-16", "https://www.nasdaq.com/articles/2-small-biotech-stocks-dreaming-big-hepatitis-c-2015-02-14", "https://www.nasdaq.com/articles/use-options-chance-buy-alny-36-discount-2015-02-23", "https://www.nasdaq.com/articles/incyte-posts-wider-than-expected-q4-loss-revenues-miss-analyst-blog-2015-02-13", "https://www.nasdaq.com/articles/alnylam-reports-narrower-loss-in-q4-focuses-on-pipeline-analyst-blog-2015-02-13", "https://www.nasdaq.com/articles/hospira-beats-on-q4-earnings-set-to-be-acquired-by-pfizer-analyst-blog-2015-02-12", "https://www.nasdaq.com/articles/loaded-alnylam-pharmaceuticals-inc-progresses-its-pipeline-2015-02-12", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-12-2015-aig-krft-cbs-dva-rsg-dlr-alny-ssnc-grpn-tco", "https://www.nasdaq.com/articles/zoetis-beats-on-q4-earnings-provides-in-line-2015-outlook-analyst-blog-2015-02-11", "https://www.nasdaq.com/articles/celgene-up-on-abraxane-getting-positive-recommendation-analyst-blog-2015-02-11", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-friday-tale-of-the-tape-2015-02-13", "https://www.nasdaq.com/articles/regeneron-beats-on-q4-earnings-driven-by-eylea-sales-analyst-blog-2015-02-10", "https://www.nasdaq.com/articles/orexigen-gives-positive-updates-on-its-weight-loss-drug-analyst-blog-2015-02-10", "https://www.nasdaq.com/articles/whats-in-store-for-acadia-healthcare-achc-this-earnings-analyst-blog-2015-02-09", "https://www.nasdaq.com/articles/why-earnings-season-could-be-great-for-alnylam-pharmaceuticals-alny-tale-of-the-tape-2015", "https://www.nasdaq.com/articles/astrazeneca-plc-beefs-precision-medicine-arsenal-2015-02-09", "https://www.nasdaq.com/articles/will-kforce-kfrc-earnings-surprise-on-improving-business-analyst-blog-2015-02-09", "https://www.nasdaq.com/articles/will-republic-services-rsg-surprise-on-q4-earnings-this-season-analyst-blog-2015-02-09", "https://www.nasdaq.com/articles/synthetic-biologics-unveils-phase-ib-safety-data-on-syn-004-analyst-blog-2015-02-11", "https://www.nasdaq.com/articles/can-gilead-boost-hcv-sales-with-health-service-deals-analyst-blog-2015-02-06", "https://www.nasdaq.com/articles/can-cerner-cern-surprise-earnings-estimates-in-q4-analyst-blog-2015-02-06", "https://www.nasdaq.com/articles/perrigo-beats-on-earnings-fy15-guidance-in-line-analyst-blog-2015-02-05", "https://www.nasdaq.com/articles/gilead-tops-q4-earnings-estimates-2015-outlook-disappoints-analyst-blog-2015-02-04", "https://www.nasdaq.com/articles/why-isis-pharmaceuticals-inc-shares-exploded-higher-11-january-2015-02-03", "https://www.nasdaq.com/articles/will-stericycle-srcl-q4-earnings-beat-on-organic-growth-analyst-blog-2015-02-03", "https://www.nasdaq.com/articles/will-atmel-atml-surprise-q4-earnings-on-organic-growth-analyst-blog-2015-02-02", "https://www.nasdaq.com/articles/will-alere-alr-surprise-earnings-estimates-this-season-analyst-blog-2015-02-06", "https://www.nasdaq.com/articles/abbvie-q4-earnings-beat-expectations-humira-strength-analyst-blog-2015-01-30", "https://www.nasdaq.com/articles/thursday-129-insider-buying-report-alny-ssb-2015-01-29", "https://www.nasdaq.com/articles/will-xerox-xrx-disappoint-q4-earnings-this-season-analyst-blog-2015-01-28", "https://www.nasdaq.com/articles/will-international-paper-ip-surprise-on-q4-earnings-analyst-blog-2015-01-27", "https://www.nasdaq.com/articles/first-week-september-18th-options-trading-alnylam-pharmaceuticals-alny-2015-01-23", "https://www.nasdaq.com/articles/mid-day-market-update-us-stocks-surge-netflix-shares-jump-upbeat-earnings-2015-01-21", "https://www.nasdaq.com/articles/will-restructuring-initiatives-drag-q4-earnings-of-ge-analyst-blog-2015-01-21", "https://www.nasdaq.com/articles/biogen-tops-q4-earnings-provides-strong-outlook-for-2015-analyst-blog-2015-01-30", "https://www.nasdaq.com/articles/pre-market-most-active-jan-21-2015-sune-ul-sne-rbs-nflx-alny-arna-mtu-tvix-aapl-bac-qcom", "https://www.nasdaq.com/articles/alnylam-to-raise-%24450-million-through-issuance-of-shares-analyst-blog-2015-01-21", "https://www.nasdaq.com/articles/mid-afternoon-market-update-alnylam-pharmaceuticals-drops-following-equity-offering", "https://www.nasdaq.com/articles/health-care-sector-update-01202015-nbs-cpxx-alny-2015-01-20", "https://www.nasdaq.com/articles/will-china-woes-impact-amphenol-aph-q4-earnings-analyst-blog-2015-01-19", "https://www.nasdaq.com/articles/should-abbvie-inc-or-gilead-sciences-buy-these-tiny-biotech-stocks-2015-01-11", "https://www.nasdaq.com/articles/cancel-jpmorgan-plenty-pre-conference-data-and-deals-digest-2015-01-10", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-mixed-unitedhealth-profit-tops-expectations-2015-01-21", "https://www.nasdaq.com/articles/how-these-3-stocks-doubled-investors-money-q4-2015-01-03", "https://www.nasdaq.com/articles/how-1-tiny-hepatitis-c-drug-developer-trounced-gilead-sciences-inc-2014-2015-01-02", "https://www.nasdaq.com/articles/commit-purchase-alnylam-pharmaceuticals-65-earn-12-annualized-using-options-2014-12-24", "https://www.nasdaq.com/articles/alnylam-provides-pipeline-update-growth-strategy-analyst-blog-2014-12-15", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-shares-march-higher-can-it-continue-tale-of-the-tape-2014-12", "https://www.nasdaq.com/articles/alnylam-reports-positive-initial-phase-i-data-on-aln-at3-analyst-blog-2014-12-09", "https://www.nasdaq.com/articles/mid-day-market-update-mcdonalds-drops-weak-november-sales-acceleron-pharma-shares-jump", "https://www.nasdaq.com/articles/health-care-sector-update-01092015-ptla-tnxp-isis-2015-01-09", "https://www.nasdaq.com/articles/why-alnylam-pharmaceuticals-alny-stock-might-be-a-great-pick-tale-of-the-tape-2014-12-04", "https://www.nasdaq.com/articles/regulus-see-further-declines-2014-11-19", "https://www.nasdaq.com/articles/alnylam-reports-positive-initial-phase-ii-data-on-revusiran-analyst-blog-2014-11-17", "https://www.nasdaq.com/articles/alnylam-adds-hepatic-infectious-disease-drugs-to-pipeline-analyst-blog-2014-11-12", "https://www.nasdaq.com/articles/isis-pharmaceuticals-inc-strikes-out-its-own-2014-11-07", "https://www.nasdaq.com/articles/alnylams-q3-loss-narrower-than-expected-pipeline-in-focus-analyst-blog-2014-11-06", "https://www.nasdaq.com/articles/investing-socially-responsible-companies-alnylam-pharmaceuticals-inc-2014-11-06", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-mixed-merck-buy-cubist-pharmaceuticals-102share-2014-12", "https://www.nasdaq.com/articles/will-perrigo-prgo-disappoint-this-earnings-season-analyst-blog-2014-11-04", "https://www.nasdaq.com/articles/will-humana-hum-miss-on-earnings-estimates-this-season-analyst-blog-2014-11-04", "https://www.nasdaq.com/articles/will-actavis-act-beat-earnings-estimates-on-forest-deal-analyst-blog-2014-11-03", "https://www.nasdaq.com/articles/is-hospira-hsp-poised-to-beat-q3-earnings-estimates-analyst-blog-2014-11-03", "https://www.nasdaq.com/articles/will-becton-dickinson-bdx-beat-q4-earnings-estimates-analyst-blog-2014-10-31", "https://www.nasdaq.com/articles/will-iot-market-focus-help-atmel-atml-beat-q3-earnings-analyst-blog-2014-10-27", "https://www.nasdaq.com/articles/5-best-biotech-stocks-buy-now-2014-10-21", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-has-ratio-right-2014-11-05", "https://www.nasdaq.com/articles/alnylam-reveals-positive-data-from-its-pipeline-candidates-analyst-blog-2014-10-15", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-jumps%3A-stock-rises-19-tale-of-the-tape-2014-10-14", "https://www.nasdaq.com/articles/alnylam-jumps-on-positive-patisiran-data-from-phase-ii-study-analyst-blog-2014-10-14", "https://www.nasdaq.com/articles/lithia-motors-dips-lowered-earnings-forecast-csx-shares-gain-2014-10-13", "https://www.nasdaq.com/articles/markets-down-targa-acquire-atlas-pipeline-atlas-energy-2014-10-13", "https://www.nasdaq.com/articles/us-stocks-fluctuate-shutterfly-shares-decline-aborted-merger-talks-2014-10-13", "https://www.nasdaq.com/articles/why-alnylam-pharmaceuticals-surged-higher-2014-10-13", "https://www.nasdaq.com/articles/moving-average-crossover-alert%3A-alnylam-pharmaceuticals-alny-tale-of-the-tape-2014-10-16", "https://www.nasdaq.com/articles/alnylam-starts-new-study-on-cardiac-amyloidosis-patients-analyst-blog-2014-09-26", "https://www.nasdaq.com/articles/alnylam-alny-to-file-clinical-trial-application-for-aln-cc5-analyst-blog-2014-09-18", "https://www.nasdaq.com/articles/alnylam-expands-pipeline-with-preeclampsia-drug-aln-agt-analyst-blog-2014-09-15", "https://www.nasdaq.com/articles/alny-makes-notable-cross-below-critical-moving-average-2014-09-05", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-breaks-above-200-day-moving-average-bullish-alny-2014-08-13", "https://www.nasdaq.com/articles/alnylams-q2-loss-wider-than-expected-pipeline-in-focus-analyst-blog-2014-08-11", "https://www.nasdaq.com/articles/sector-update-health-care-2014-08-07-1", "https://www.nasdaq.com/articles/alnylam-begins-new-study-on-hepatic-porphyrias-patients-analyst-blog-2014-10-06", "https://www.nasdaq.com/articles/alny-crosses-below-key-moving-average-level-2014-06-26", "https://www.nasdaq.com/articles/alnylam-up-on-narrower-than-expected-q1-loss-analyst-blog-2014-05-12", "https://www.nasdaq.com/articles/sanofi-misses-on-q1-earnings-lackluster-revs-analyst-blog-2014-04-30", "https://www.nasdaq.com/articles/thursday-sector-laggards-biotechnology-drugs-2014-04-10", "https://www.nasdaq.com/articles/thursdays-etf-movers-thrk-xbi-2014-04-10", "https://www.nasdaq.com/articles/epo-upholds-alnylams-mcswiggen-patent-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/sanofi-ucb-ink-deal-analyst-blog-2014-03-12", "https://www.nasdaq.com/articles/sector-update-health-care-shares-higher-pre-market-2014-08-07", "https://www.nasdaq.com/articles/sanofi-ardelyx-ink-deal-analyst-blog-2014-02-25", "https://www.nasdaq.com/articles/bull-day-alexion-pharma-alxn-bull-day-2014-02-24", "https://www.nasdaq.com/articles/alnylam-widens-q4-loss-analyst-blog-2014-02-14", "https://www.nasdaq.com/articles/ishares-russell-2000-etf-experiences-big-inflow-2014-02-14", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-13-2014-aig-krft-lbtya-alsn-alny-brcd-im-wri-cgnx-clf", "https://www.nasdaq.com/articles/sanofis-q4-earnings-beat-overcast-by-weak-guidance-analyst-blog-2014-02-07", "https://www.nasdaq.com/articles/gilead-beats-on-earnings-revs-sovaldi-off-to-a-flier-analyst-blog-2014-02-05", "https://www.nasdaq.com/articles/are-these-biotechs-part-of-your-portfolio-analyst-blog-2014-03-03", "https://www.nasdaq.com/articles/pipeline-progress-at-alnylam-analyst-blog-2014-01-24", "https://www.nasdaq.com/articles/orphan-drug-status-for-alexions-solaris-analyst-blog-2014-01-22", "https://www.nasdaq.com/articles/biotech-stock-roundup-sarepta-spikes-data-alnylam-deal-analyst-blog-2014-01-22", "https://www.nasdaq.com/articles/prospects-bright-at-alexion-pharma-analyst-blog-2014-01-16", "https://www.nasdaq.com/articles/biotech-stock-roundup-intercept-pharma-grabs-limelight-analyst-blog-2014-01-15", "https://www.nasdaq.com/articles/company-news-for-january-14-2014-corporate-summary-2014-01-14", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-soars%3A-stock-up-40.9-tale-of-the-tape-2014-01-14", "https://www.nasdaq.com/articles/another-strong-earnings-beat-from-amgen-analyst-blog-2014-01-29", "https://www.nasdaq.com/articles/mid-day-market-update-sodastream-drops-after-weak-outlook-beam-shares-spike-higher-2014-01", "https://www.nasdaq.com/articles/european-shares-rise-easier-basel-regulations-2014-01-13", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-lululemon-lowers-q4-outlook-2014-01-13", "https://www.nasdaq.com/articles/pipeline-update-at-alnylam-analyst-blog-2014-01-13", "https://www.nasdaq.com/articles/mid-afternoon-market-update-markets-dip-despite-large-amount-ma-2014-01-13", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-alny-new-analyst-report-zacks-equity-research-zacks-equity", "https://www.nasdaq.com/articles/pipeline-progress-at-alnylam-analyst-blog-2013-12-23", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc.-alny-enters-overbought-territory-tale-of-the-tape-2014-01-14", "https://www.nasdaq.com/articles/biotech-stock-roundup-vanda-soars-sarepta-slumps-analyst-blog-2013-11-20", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-11-18-1", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-mixed-carefusion-agrees-acquire-general-electric-2013-11", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-11-18-2", "https://www.nasdaq.com/articles/wider-than-expected-q3-loss-at-alnylam-analyst-blog-2013-11-07", "https://www.nasdaq.com/articles/healthcare-stocks-sliding-close-alynylam-pharma-sinks-after-net-loss-larger-forecast-2013", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-11-07-0", "https://www.nasdaq.com/articles/alnylam-earns-milestone-payment-analyst-blog-2013-11-26", "https://www.nasdaq.com/articles/pipeline-progress-at-alnylam-analyst-blog-2013-10-14", "https://www.nasdaq.com/articles/pipeline-update-at-alnylam-analyst-blog-2013-10-08", "https://www.nasdaq.com/articles/pipeline-progress-at-alnylam-analyst-blog-2013-10-03", "https://www.nasdaq.com/articles/alnylam-up-on-positive-phase-i-data-analyst-blog-2013-09-24", "https://www.nasdaq.com/articles/orphan-drug-status-for-aegrs-juxtapid-in-japan-analyst-blog-2013-09-10", "https://www.nasdaq.com/articles/data-published-on-alnylams-attr-candidates-analyst-blog-2013-08-29", "https://www.nasdaq.com/articles/alnylam-wins-orphan-drug-status-analyst-blog-2013-08-21", "https://www.nasdaq.com/articles/pipeline-progress-at-alnylam-analyst-blog-2013-10-30", "https://www.nasdaq.com/articles/narrower-than-expected-q2-loss-at-alnylam-analyst-blog-2013-08-14", "https://www.nasdaq.com/articles/aegerions-lojuxta-gets-eu-approval-analyst-blog-2013-08-05", "https://www.nasdaq.com/articles/best-stocks-isis-gilead-celgene-and-regeneron-take-over-top-ranks-2013-07-29", "https://www.nasdaq.com/articles/market-wrap-friday-july-12-stocks-rise-sp-500-closes-new-all-time-high-2013-07-12", "https://www.nasdaq.com/articles/northera-nda-resubmitted-by-chelsea-analyst-blog-2013-07-11", "https://www.nasdaq.com/articles/market-wrap-thursday-july-11-market-jumps-dovish-bernanke-comments-2013-07-11", "https://www.nasdaq.com/articles/australian-approval-for-vertex-kalydeco-analyst-blog-2013-07-10", "https://www.nasdaq.com/articles/good-news-for-alnylam-analyst-blog-2013-08-19", "https://www.nasdaq.com/articles/positive-data-on-alnylams-candidate-analyst-blog-2013-07-01", "https://www.nasdaq.com/articles/celgene-inks-oncology-deal-analyst-blog-2013-06-27", "https://www.nasdaq.com/articles/celgene-presents-revlimid-data-analyst-blog-2013-06-26", "https://www.nasdaq.com/articles/gilead-retained-at-neutral-analyst-blog-2013-06-25", "https://www.nasdaq.com/articles/chmp-positive-on-aegerions-lojuxta-analyst-blog-2013-06-03", "https://www.nasdaq.com/articles/alnylam-narrows-loss-sales-fall-analyst-blog-2013-05-07", "https://www.nasdaq.com/articles/pipeline-progresses-at-viropharma-analyst-blog-2013-04-23", "https://www.nasdaq.com/articles/biomarin-files-vimizim-ma-in-brazil-analyst-blog-2013-07-05", "https://www.nasdaq.com/articles/alnylam-initiates-aln-ttrsc-study-analyst-blog-2013-03-19", "https://www.nasdaq.com/articles/loss-widens-at-alnylam-sales-fall-analyst-blog-2013-02-08", "https://www.nasdaq.com/articles/alnylam-mdco-join-for-aln-pcs-analyst-blog-2013-02-05", "https://www.nasdaq.com/articles/alnylams-aln-vsp-data-published-analyst-blog-2013-01-31", "https://www.nasdaq.com/articles/mid-morning-market-update-goldman-sachs-crushes-earnings-research-motion-rises-visa", "https://www.nasdaq.com/articles/alnylam-prices-public-offering-analyst-blog-2013-01-16", "https://www.nasdaq.com/articles/best-stocks-biotech-still-holding-top-spots-2013-04-22", "https://www.nasdaq.com/articles/pipeline-update-from-alnylam-analyst-blog-2013-01-08", "https://www.nasdaq.com/articles/alnylam-tekmira-settle-up-analyst-blog-2012-11-19", "https://www.nasdaq.com/articles/isis-misses-on-both-counts-analyst-blog-2012-11-07", "https://www.nasdaq.com/articles/revenues-decline-at-alnylam-analyst-blog-2012-11-07", "https://www.nasdaq.com/articles/casey-analyst-forecasts-explosive-biotech-growth-2012-10-17", "https://www.nasdaq.com/articles/isis-pharma-owns-18-of-regulus-analyst-blog-2012-10-12", "https://www.nasdaq.com/articles/alnylam-isis-venture-prices-ipo-analyst-blog-2012-10-05", "https://www.nasdaq.com/articles/alnylam-to-raise-%24125-million-analyst-blog-2013-01-15", "https://www.nasdaq.com/articles/alnylam-monsanto-collaborate-analyst-blog-2012-08-29", "https://www.nasdaq.com/articles/alnylam-isiss-regulus-to-go-public-analyst-blog-2012-08-22", "https://www.nasdaq.com/articles/biogen-inks-deal-with-regulus-analyst-blog-2012-08-16", "https://www.nasdaq.com/articles/alnylam-pharma-revs-in-line-analyst-blog-2012-08-07", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-monday-tale-of-the-tape-2012-08-06", "https://www.nasdaq.com/articles/alnylam-earns-milestone-payment-analyst-blog-2012-08-06", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-thursday-tale-of-the-tape-2012-08-02", "https://www.nasdaq.com/articles/alnylam-presents-data-on-aln-rsv01-analyst-blog-2012-09-06", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-tuesday-tale-of-the-tape-2012-07-24", "https://www.nasdaq.com/articles/positive-data-on-alnylam-candidate-analyst-blog-2012-07-23", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-friday-tale-of-the-tape-2012-07-20", "https://www.nasdaq.com/articles/company-news-for-july-17-2012-corporate-summary-2012-07-17", "https://www.nasdaq.com/articles/alnylam-inks-oncology-deal-analyst-blog-2012-07-13", "https://www.nasdaq.com/articles/orphan-status-for-alnylam-drug-analyst-blog-2012-06-21", "https://www.nasdaq.com/articles/how-short-ratio-can-lead-big-gains-screen-week-2012-06-12", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-friday-tale-of-the-tape-2012-07-27", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-sanofi-regeneron-alnylam-and-coach-press-releases", "https://www.nasdaq.com/articles/encouraging-data-on-amgen-candidate-analyst-blog-2012-03-27", "https://www.nasdaq.com/articles/company-news-for-february-15-2012-corporate-summary-2012-02-15", "https://www.nasdaq.com/articles/alnylam-delivers-in-line-numbers-analyst-blog-2012-02-13", "https://www.nasdaq.com/articles/alnylam-gets-new-patent-analyst-blog-2012-02-01", "https://www.nasdaq.com/articles/alnylam-to-cut-33-jobs-analyst-blog-2012-01-23", "https://www.nasdaq.com/articles/alnylam-down-to-neutral-analyst-blog-2012-01-20", "https://www.nasdaq.com/articles/alnylam-narrows-loss-analyst-blog-2012-05-04", "https://www.nasdaq.com/articles/still-bullish-on-alnylam-analyst-blog-2011-12-07", "https://www.nasdaq.com/articles/alnylam-completes-trial-enrollment-analyst-blog-2011-12-01", "https://www.nasdaq.com/articles/alnylam-reveals-alnttr01-trial-data-analyst-blog-2011-11-25", "https://www.nasdaq.com/articles/hearty-profits-companies-racing-develop-next-big-cholesterol-drug-2011-08-30", "https://www.nasdaq.com/articles/options-ideas-24-healthcare-stocks-bullish-options-sentiment-2011-06-07", "https://www.nasdaq.com/articles/4-small-caps-could-pop-2010-12-10", "https://www.nasdaq.com/articles/alnylam-states-preclinical-data-analyst-blog-2011-12-30"], "Content": []}